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Hematopoietic stem cell transplant (HSCT) patients are especially susceptible to 
lung infections, despite immune reconstitution.  In a mouse model of syngeneic bone 
marrow transplantation (BMT), we previously reported that prostaglandin E2 (PGE2) is 
overproduced in lungs of BMT mice, significantly impairing pulmonary host defense 
against Pseudomonas aeruginosa.  This impairment in pulmonary host defense post-
BMT is also marked by diminished alveolar macrophage (AM) function.  These data 
were generated using total body irradiation (TBI) as a means to ablate host bone marrow.  
Therefore, we wanted to determine whether the use of clinically relevant chemotherapy 
regimens to ablate host bone marrow would result in similar findings.  We compared 
donor-cell reconstitution, pulmonary host defense, and PGE2 production among control 
and BMT mice conditioned with either TBI or chemotherapy.  Dual chemotherapy 
conditioned mice had a lower frequency of donor-derived cells compared to TBI; 
however, both groups displayed similar impairment in AM host defense and bacterial 
clearance following P. aeruginosa pneumonia.  Furthermore, impairment in AM host 
defense was directly related to overproduction of PGE2 in both groups.  These data 
suggest that compared to TBI, use of chemotherapy conditioning results in similar PGE2-
mediated suppression of pulmonary host defense in BMT mice, despite reduced 
efficiency of donor-cell reconstitution.  To determine a mechanism for PGE2-mediated 
suppression of pulmonary host defense post-BMT, roles for inhibitory molecules 




on chromosome 10 (PTEN) were examined.  We found that IRAK-M expression and 
PTEN phosphatase activity were elevated in BMT AMs relative to control AMs, and this 
was related to AM overproduction of PGE2.   Furthermore, genetic ablation of IRAK-M 
in the bone marrow of BMT mice restored host defense against P. aeruginosa.  Similarly, 
WT mice transplanted with myeloid-specific PTEN knockout (KO) bone marrow also 
displayed improved host defense against P. aeruginosa.  Despite overproduction of 
PGE2, AM phagocytosis, killing, and production of proinflammatory mediators were 
restored in the absence of either IRAK-M or PTEN post-BMT.  Overall, these data 
demonstrate that the absence of either IRAK-M or PTEN in the hematopoietic 
compartment post-BMT enhances pulmonary host defense and mitigates AM sensitivity 




CHAPTER 1: Introduction 
 
The Mammalian Immune System 
 
The mammalian immune system is a complex network of innate and adaptive 
immune cells which arise from hematopoietic stem cell progenitors in the bone marrow 
(1, 2).  Innate immune cells are derived from myeloid and lymphoid progenitors and 
consist of macrophages, monocytes, dendritic cells, natural killer (NK) cells, and 
granulocytes such as neutrophils, eosinophils, and basophils.  T and B lymphocytes make 
up the adaptive arm of the immune system and are derived from lymphoid progenitors (1, 
2).  The purpose of the immune system is to discriminate between self and non-self 
antigens and to eliminate anything recognized as non-self via cell-mediated and humoral 
responses.  In the event that a particular antigen is recognized as non-self, such as an 
invading pathogen or tumor antigen, the host elicits an inflammatory response mediated 
initially by antigen presenting cells (APCs) of the innate immune system (such as 
dendritic cells and tissue macrophages) (3, 4).  Pathogen-associated molecular patterns 
(PAMPs) on microbes, as well as certain endogenous proteins released from tumors and 
damaged tissues, engage pattern recognition receptors (PRRs) expressed on the surface of 
APCs.  Binding of these ―danger signals‖ to PRRs activates a number of signaling 
pathways to induce transcription and subsequent release of proinflammatory cytokines 




immune cells to the site of infection (such as neutrophils or eosinophils) and facilitates 
activation of the adaptive immune system for antigen-specific clearance of pathogen and 
the resolution of tissue damage (6).   
 
Hematopoietic Stem Cell Transplantation 
 Malignancy or defective function of bone marrow and bone marrow-derived cells 
can severely disrupt multiple aspects of immune homeostasis, responsiveness, and 
resolution.  Examples of such disorders include: severe combined immunodeficiency, 
leukemia, sickle cell anemia, glycogen storage disease, and multiple myeloma (7).  
Treating such malignant and non-malignant disorders of the immune system often 
requires hematopoietic stem cell transplantation (HSCT).   
The process of HSCT involves ablation of host bone marrow and reinfusion of the 
host with his/her own bone marrow (autologous HSCT), genetically identical bone 
marrow (syngeneic HSCT), or bone marrow from a histocompatible, HLA matched 
donor (allogeneic HSCT) (8). Preparative regimens used to ablate host bone marrow 
typically involve a fractionated dose of radiation (known as total body irradiation; TBI), 
treatment with high dose chemotherapy drugs (such as cyclophosphamide and/or 
busulfan), or a combination of both TBI and chemotherapy (7).  In most cases, ablating 
the host bone marrow via these methods eradicates the underlying disease or malignancy 
of the immune system and allows for engraftment of transplanted donor stem cells.  HSC 
grafts are composed of immature and mature hematopoietic cells and can be obtained 
directly from the bone marrow, umbilical cord blood, or peripheral blood stem cells 




Effectiveness of engraftment (or potency) is dependent on the amount of cells 
present in the graft that express the CD34 antigen— a well characterized cell surface 
marker for cells of hematopoietic origin.  Moreover, immune potency is determined 
based on the number of certain immune cell types present in the graft including: CD3 
cells, natural killer cells, and dendritic cells (9).  The greater the number of these immune 
cell populations within the graft, the faster the kinetics of immune reconstitution.  In 
allogeneic HSCT, T cell depletion is often performed to reduce the risk of graft-versus-
host disease (GVHD), a condition where donor T cells recognize certain host minor and 
major MHC antigens as foreign and mount an immune response against host cells 
expressing these antigens.  However, depletion of donor T cells can lead to other 
complications, such as increased risk of graft rejection and delayed reconstitution of T 
and B cells (9). 
 
Immune Reconstitution and Functional Recovery 
Following HSCT, donor-derived stem cells undergo hematopoiesis to reestablish 
the entire immune system.  The innate immune compartment is the first to emerge 
following HSCT (8, 10, 11).  Neutrophils are the first leukocytes to recover between 
weeks two and four post-HSCT; however, restored host defense function in neutrophils is 
not achieved until as early as two months post- HSCT (8).  Full reconstitution of 
monocytes and tissue macrophages ranges between several weeks to months post-HSCT.  
Monocyte numbers are restored around day 41 post-HSCT, and tissue macrophages (such 
as in the lung) are restored nearly three months post-HSCT (12).  The kinetics of DC 




GVHD (13-15).  DC subsets can be found as early as two weeks post-HSCT; however, 
the functional recovery of donor-derived DCs is not well characterized.    NK cells 
recover in cellularity between one to two months post-HSCT, and functional recovery is 
reported to coincide with complete reconstitution of this particular immune cell type (8, 
10, 12).   
The kinetics of reconstitution and the functional recovery of B cells and T cells 
are fairly well described.  B cell numbers are reestablished three months post-HSCT; 
however, immunoglobulin (Ig) production to new and previously encountered antigens is 
not fully restored for as long as two years post-HSCT (10, 16).  Mature CD3 T cells 
begin to emerge approximately 15 days post-HSCT, and like B cells, reach normal counts 
by three months post-HSCT.  However, in terms of T cell subsets, CD4 T cell numbers 
are decreased relative to non-transplant patients and do not reach counts that can provide 
effective immunity for as long as six to twelve months post-HSCT (11).  CD8 T cell 
reconstitution occurs more rapidly than CD4 T cell reconstitution, with total counts 
recovering within a few months following HSCT (8, 10).  As with certain innate immune 
cell types, functional recovery of B and T cell subsets can vary depending on the HSC 
donor source, T cell depletion of graft, and the presence GVHD (8). 
 
Outcomes of HSCT 
 Although there is significant therapeutic benefit from use of HSCT to treat 
malignant and genetic abnormalities of the immune system, the success of HSCT is often 
limited due to a number of pre- and post-transplant related complications (17).  In 




delays in immune reconstitution, defective immune function, onset of GVHD, and use of 
immunosuppressive drug therapy (7, 8).  Furthermore, use of TBI and chemotherapy 
preparative regimens typically induces many of the non-infectious complications 
observed in HSCT patients, such as severe organ toxicity (7).   The 100 day mortality rate 
has been reported to range from 10 to 40% in allogeneic transplant patients.  Mortality in 
these patients results mainly from GVHD, multiorgan failure, and interstitial pneumonitis 
(18).  Autologous transplant recipients have a 100 day mortality range of 5 to 20% with 
the major causes of death being relapse of underlying disease and second cancer (18).  
Infections are reported in about half of all patients within the first two years after HSCT, 
and mortality rates can be as high as 50% depending on the type of infection, HSC 
source, and the presence of GVHD (19).   
 
Non-Infectious Complications of HSCT 
  Non-infectious complications following HSCT can be either acute or chronic and 
often result from GVHD or toxicity caused by the type of conditioning regimen used (7).  
One major non-infectious complication is mucositis.  Mucositis is painful ulceration of 
the mucous membranes of the intestinal tract and oral cavity and affects the majority of 
HSCT patients receiving TBI, high-dose chemotherapy, and certain anti-GVHD drug 
therapies (20, 21).  Sinusoidal obstructive syndrome of the liver is another major non-
infectious complication (22), where conditioning-induced damage of venules and 
sinusoids leads to obstruction of hepatic circulation, hepatocyte injury, and multiorgan 
failure (22).  Non-infectious pulmonary complications are also a significant problem 




obliterans, and pulmonary edema (18). GVHD is another serious complication of 
allogeneic HSCT and may occur in the gastrointestinal tract, skin, or lungs (7).  Major 
consequences of acute GVHD include: gastrointestinal problems, jaundice, rash, and 
delayed immune reconstitution and responsiveness to infection.  On the other hand, 
chronic GVHD is characterized by malabsorption, loss of self-tolerance, and generalized 
immunosuppression (7, 23).  Moreover, steroids and other drugs used to suppress T cell 
responses during GVHD cause severe immunodeficiency and further increase the risk of 
infection (24-26).   
 
Infectious Complications of HSCT 
Infectious risk and type of infection following HSCT are generally dictated by the 
HSC source, conditioning regimens, the presence of GVHD, and post-transplant therapy 
(9).  Specific infectious risks are divided among three phases following HSCT: pre-
engraftment (day 0 to 30), early post-engraftment (day 30 to 100), and late post-
engraftment (day 100 and beyond) (9).  Pre-engraftment is characterized by neutropenia 
(a severe deficit in the number of functional neutrophils) (9, 17) and mucosal injury (7).  
These conditions increase the risk for both Gram-negative and Gram-positive bacterial 
infections of the lung, skin, urogenital and intestinal tract, and oral cavity (9).   In 
particular, the mortality rate for bacterial infections of the lung is especially high, ranging 
from 22 to 29% for BMT patients (27).  Nearly half of all bacterial infections post-HSCT 
are Gram-negative infections, and are predominately caused by Pseudomonas aeruginosa 
and Klebsiella pneumonia (9).    Of the Gram-positive bacterial infections in HSCT 




viridians streptococci, and the remaining are caused by Staphylococcus aureus, 
Legionella, and various others (9, 27).  Invasive fungal infections, such as Candida, are 
also present during this phase, with the lung being a primary site of infection (28, 29).  
Viruses also pose a major risk for infection (9, 30).  During this phase, human 
herpesviruses -1, -2, and -6 commonly reactivate within 1 to 2 weeks post-HSCT in 
seropositive individuals (9, 27).  Lung-associated viruses such as influenza, respiratory 
syncytial virus, and adenovirus also pose infectious risks during pre-engraftment (27). 
Infectious risk reduces dramatically during the early post-engraftment phase and 
even more so during the late engraftment phase, due to resolved neutropenia and 
reconstitution of many immune cell types (9, 30).  However, deficiencies in immune 
function as well as the presence of GVHD during the post-engraftment phases render 
HSCT recipients susceptible to infection.  Bacterial and fungal infections remain 
common at catheter sites as well as in the lung (9, 18).  Pulmonary infections caused by 
cytomegalovirus and Epstein-Barr virus are also reported during these stages (9, 18, 30). 
 
P. aeruginosa Pneumonia 
 Pulmonary complications occur in up to 60% of HSCT patients, and infectious 
pneumonia remains one of the leading causes of mortality (19).  In particular, P. 
aeruginosa acute lung infection is reported to have a mortality rate of as high as 40% in 
some studies (31).  This high incidence is likely due to the ubiquitous and opportunistic 
nature of P. aeruginosa.  P. aeruginosa is present throughout the environment including: 
water systems, air, soil, and vegetation (32).  P. aeruginosa has a poor ability to adhere to 




by burns, chemicals, infection, nutrient deprivation, or other insults, P. aeruginosa can 
readily establish infection (33).  As a result, P. aeruginosa is common cause of infection 
for immunocompromised individuals, such as HSCT patients.  Moreover, infectious risk 
in these individuals is exacerbated given the intrinsic resistance of P. aeruginosa to a 
variety of antibiotics and disinfectants (32, 33).  Therefore, it is important to understand 
normal host defense against this pathogen, particularly in the lung, and how it may be 
altered in the setting of HSCT. 
 
Pulmonary Immunity and Host Defense Against P. aeruginosa 
 During respiration, the lung is exposed to various airborne pathogens and 
particles.  This includes bacteria, mycobacteria, fungi, viruses, and particulate matter (5).  
Consequently, the host has evolved various mechanical and immune defenses to trap and 
clear away pathogens and debris that enter into  airways (4).  Mechanical host defenses 
are the physical barriers encountered by particles and pathogens as they enter the airways.  
These barriers include upper airway structures, cilia, and mucus which trap inhaled 
agents (4).  However, particles less than 5 µm in diameter can easily pass through these 
mechanical structures of the upper airways and enter the terminal airways (4).  To 
prevent colonization of pathogens which bypass these mechanical structures, immune 
defenses play a critical role.  These defenses include various antimicrobial factors, 
humoral opsonins, proinflammatory mediators, resident and recruited lung phagocytes, 
structural cells, and antigen-specific B- and T-cell responses. 
 Pulmonary host defense against P. aeruginosa is initially mediated by airway 




aeruginosa trapped in the mucosal lining of the upper and lower respiratory tract is 
recognized by opsonins and PRRs on AM and epithelial cell surfaces.  These events 
trigger AM phagocytosis/killing and production of antimicrobial factors, cytokines, and 
chemokines from AMs and structural cells (3, 32).  Neutrophils are quickly recruited to 
the site of infection and are essential for complete phagocytic clearance and bacterial 
killing of P. aeruginosa (6).  Additionally, monocytes are also recruited from the 
circulation and given that the phagocytic ability of this cell type is rather limited, their 
primary role appears to be the production of proinflammatory mediators and 
antimicrobial factors (3, 34).  Collectively, these innate immune defenses work together 




Defensins are a family of single-chain, cationic peptides ranging in molecular 
weight from 2 to 6 kDa.  Defensins are broken up into three groups (α, β, and θ) based on 
the sequence relationship between the three intramolecular disulfide bonds formed by six 
cysteine residues within the peptide (35).  α-defensins have been identified in both 
humans and rodents and are produced by neutrophils, certain macrophages, and Paneth 
cells in the small intestine (36-38).  β-defensins have been identified in virtually all 
mammals studied and are produced mainly by epithelial cells of the lung, skin, intestine, 
and urogenital tract.  θ-defensins are not well described and have only been identified in 




Defensins are produced under basal conditions and in response to infection or 
proinflammatory cytokine stimulus. In mice, β-defensin is upregulated by lung epithelial 
cells following bacterial infection or treatment with tumor necrosis factor (TNF)-α, IL-
1β, or LPS (35).  Defensins can inactivate and kill both Gram-negative and Gram-
positive bacteria, fungi, and enveloped viruses (4).  The mechanism of direct defensin 
microbial killing/inactivation is unknown; however, it is thought that defensins 
permeabilize microbial membranes by inserting into phospholipid membranes and 
forming pores that result in microbial lysis (35).  In particular, human β-defensin 2 is 
critical for bacterial killing of P. aeruginosa and is rapidly induced in response to 
infection (40).  Other important functions of defensins include: enhancing macrophage 
phagocytosis, enhancing bronchoepithelial cell IL-8 production for neutrophil 
recruitment, increasing monocyte TNF-α and IL-1 production, and decreasing monocyte 
IL-10 production (4, 35). 
 
Lactoferrin 
 Lactoferrin is a 80 kDa glycoprotein that has been detected in both humans and 
mice (41).  Lactoferrin is stored and released from secondary granules of neutrophils and 
inhibits microbial growth by limiting the amount of free iron available for microorganism 
metabolism and growth (42).  Lactoferrin is known to inhibit the growth of Gram-
negative bacteria and fungi and to prevent replication of viruses, such as CMV (42).  
Lactoferrin can also directly kill and inhibit biofilm formation of bacteria, such as P. 




thought that lactoferrin binds to the surface of microbes and induces microbial lysis by 
permeablizing the outer membrane (42).   
 
Cathelicidins 
Cathelicidins are bipartite molecules with a conserved N-terminal domain and a 
highly variable antimicrobial C-terminal domain (44).  The single cathelicidin identified 
in humans is hCAP-18, and proteolytic cleaveage of this peptide produces the 
antimicrobial product, LL-37.  The murine cathelicidin, cathelicidin-related antimicrobial 
peptide (CRAMP),  has strong homology to LL-37 (44).  LL-37 and CRAMP are both 
found in secondary granules of neutrophils and are also produced by epithelial cells (such 
as in the lung) during injury and infection (41).  LL-37 production has also been reported 
in T cells, NK cells, B cells, γδ-T cells, and monocytes.  The antimicrobial functions of 
cathelicidins include: binding to LPS to reduce pathogen toxicity and direct killing of 
bacteria, such as P. aeruginosa, via undescribed mechanisms.  Moreover, LL-37 acts as a 
chemotactic factor for monocytes and neutrophils via binding to the G protein coupled 
receptor (GPCR), peptide-like receptor-1, which is expressed on these immune cells (44). 
 
Lysozyme 
 Lysozyme is a 14 kDa protein that permeablizes bacterial cell walls via enzymatic 
and non-enzymatic mechanisms.  Enzymatic antimicrobial properties of lysozyme 
involve the breakdown of the bacterial cell wall component, peptidoglycan (41, 42). The 
mechanism for non-enzymatic bacterial cell wall lysis is not known.  Lysozyme is 




within phagocytic compartments (42).  While humans have only one lysozyme gene, 
mice have two lysozyme genes (lysozyme-M and -P), which are differentially expressed.  
Lysozyme M is expressed in phagocytes and epithelial cells, and lysozyme P is expressed 
in Paneth cells in the small intestine (41).  Lysozyme is highly effective against Gram-
positive species; however, lysozyme alone is ineffective in microbial killing of Gram-
negative species and requires the activity of other antimicrobial factors, such as 
lactoferrin and antibody-complement, to degrade the outer layer of Gram-negative cell 
walls (41).  Nevertheless, studies have demonstrated the importance of lysozyme in 
pulmonary host defense against P. aeruginosa.  For example, over-expression of 
lysozyme in the lung enhances bacterial clearance, reduces bacterial dissemination to the 




 Collagenous C-type lectins, or collectins, are a large group of multimeric 
carbohydrate-binding proteins.  Collectins typically aggregate into trimers to form a 
lectin domain that recognizes highly conserved sugar patterns on viral, bacterial, yeast, 
and fungal pathogens (4).  Collectin binding to microbial targets results in opsonization 
and clustering of pathogens.  This ultimately neutralizes the pathogen and enhances 
phagocytic uptake (46).  There are three major types of collectins including: surfactant 
proteins (SPs), lung collectin, and mannose-binding lectin (MBL).  The major group of 




There are two known SPs in human and mouse that function in lung immune 
responses: SP-A and SP-D.  Both SP-A and SP-D are produced by type II alveolar 
epithelial cells (AECs) and Clara cells.  SP-D is also produced in other tissues, such as 
the intestine (46).  SP-A and SP-D have multiple immunomodulatory functions.  One 
major function of SPs in the lung is to dampen immune responsiveness to ubiquitous 
pathogens (48, 49).  Furthermore, SP-A and -D can bind to toll-like receptors (TLR)-4 
and -2 and inhibit TLR-mediated proinflammatory cytokine production (50-52).  
However, some studies have demonstrated that surfactants are capable of inducing 
inflammatory responses.  SP-A has been reported to stimulate both scavenger and 
mannose receptor expression in AMs, to enhance macrophage and neutrophil chemotaxis, 
and to stimulate cytokine and reactive oxygen species (ROS) production in phagocytes 
(46).  Furthermore, SP-A and -D bind to AMs with high affinity and enhance phagocytic 
uptake of P. aeruginosa (53).  It has also been reported that deficiency of SPs in mice 
severely impairs bacterial clearance following P. aeruginosa lung infection (54, 55).  
 
Complement 
 The complement system is composed of more than 20 plasma and cell membrane 
proteins that have important functions in both innate and adaptive immunity (56).  
Complement proteins circulate as zymogens and become activated in cascade fashion in 
response to inflammatory stimuli.  Three complement activation pathways have been 
described: the classical pathway, the MBL or lectin pathway, and the alternative pathway  
(56).  In the classical pathway, the complement protein C1q binds to antibodies bound to 




in proteolytic cleavage of the complement protein C3 into C3a and C3b (57).  Following 
C3 cleavage into C3a and C3b, C3b undergoes a conformational change that allows for 
binding and opsonization of pathogens.  On the pathogen surface, C3b is further cleaved 
into smaller fragments that are recognized by specific complement receptors (CR) 
expressed on phagocyte cell surfaces (57).  These receptors include: CR1 through CR4 
and CRIg.  The lectin pathway is activated following binding of MBL or ficolins to 
mannose and other sugars on pathogen surfaces.  This interaction initiates cleavage of C4 
and C2 complement proteins and formation of C4b and C3b for pathogen opsonization 
(57).  The alternative pathway involves spontaneous cleavage of C3 to form C3a and C3b 
(56).  Another consequence of activation of all three pathways is the formation of C5a 
protein, which can function in concert with C3a as a chemokine to recruit phagocytes to 
sites of infection (58). Complement proteins C5 through C9 are also known to form a 
cascade that leads to assembly of a membrane-attack complex.  This complex mediates 
microbial lysis by generating pores in the pathogen cell wall (58).  Recognition and 




 Igs, also called antibodies, are proteins composed of four polypeptide chains (two 
light and two heavy) connected by two disulfide bonds (59).  Igs are the central factor of 
adaptive humoral immunity, and following antigen stimulation, Igs are generated and 
optimized for functional activity by mature B cells and plasma cells. There are five 




further broken down into several subclasses (59).  The main functions of Igs in immunity 
are the mediation of classical complement activation (IgG1/2/3 and IgM), alternative 
complement activation (IgA, IgD, and IgG1/2/3),  Fc receptor-mediated phagocytosis 
(IgG1/3, and IgA), inflammatory mediator release from granulocytes (IgE), cytotoxicity 
(IgG1/3), and receptor-mediated transport across mucosa (IgA and IgM) (59).  During P. 
aeruginosa infection in mice, increases in antigen specific IgG1 and IgG2b are detected 
(60).  This may be critical for chronic or repeated P. aeruginosa infections, where IgG 
can opsonize P. aeruginosa and facilitate Fc gamma receptor (FcγR)-mediated 
phagocytosis.    
 
TLRs 
 TLRs are a well described group of PRRs that belong to the TLR/Interleukin-1 
receptor (IL-1R) or TIR superfamily.  More than a dozen TLRs have been identified in 
humans and mice to date (61).  Both TLRs and IL-1Rs have a common intracellular TIR 
domain; however, TLRs have a leucine-rich repeat motif in the extracellular domain, 
while IL-1Rs have an immunoglobulin containing extracellular domain (61, 62).  
Activation of TLRs and IL-1Rs recruits the adaptor molecule myeloid differentiation 
primary response gene 88 (MyD88) to their TIR domains.  Members of the interleukin-1 
receptor associated kinase (IRAK) family and various other proteins bind to MyD88 and 
form an adaptor complex that activates signaling pathways for induction of 
proinflammatory gene transcription (61, 63).  TLR3 signaling, however, is not mediated 
through MyD88 but the adaptor protein, TIR-domain-containing adaptor inducing 




Cytoplasmic PRRs have also been identified and include NOD-like receptors (NLRs) and 
retinoic-acid-inducible gene I-like RNA helicases. 
During P. aeruginosa lung infection, TLRs and NLRs expressed by lung 
epithelial cells and phagocytes are engaged and induce the production of 
proinflammatory mediators and antimicrobial factors (3, 5).  Specific roles for MyD88, 
TLR2, and TLR4 have been identified in pulmonary host defense against P. aeruginosa.  
Mice deficient in expression of MyD88, TLR2, or  TLR4 display increased bacterial 
burden and decreased neutrophil influx during P. aeruginosa pneumonia (64-66).  
Additionally, the cytoplasmic PRR, NOD1, has been shown to bind to P. aeruginosa 
peptidoglycan, and deficient expression of NOD1 reduces proinflammatory cytokine 
production in cells inoculated with P. aeruginosa (67).   
 
Proinflammatory Mediators 
Key inflammatory mediators produced by AMs and AECs in response to 
infectious stimulus include: TNF-α, interleukin (IL)-1, IL-8 or macrophage inflammatory 
protein (MIP)-2, IL-10, prostaglandin E2 (PGE2), and leukotrienes (LT) such as LTB4 (4, 
68). Production of TNF-α and IL-1 is critical for induction of chemokines, such as IL-8, 
which recruit neutrophils to the site of infection (69).  LTB4 is also produced in response 
to infectious stimulus for neutrophil recruitment (70).  IFN-γ is a critical activator of 
AMs, serving to enhance microbial killing and further TNF-α release (71).  PGE2 and IL-




proinflammatory cytokine production, phagocytosis, and microbial killing in phagocytes 
(72, 73). 
Multiple proinflammatory mediators are produced during P. aeruginosa lung 
infection.  Proinflammatory cytokines detected in bronchoalveolar lavage (BAL) fluid 
following acute P. aeruginosa lung infection in mice include: TNF-α, IL-1β, IFN-γ and 
IL-6 (74).  The eicosanoids, PGE2 and cysteinyl-LTs (cys-LTs), are also detectable at 
high levels in lung (68).   Chemokines IL-8/MIP-2, KC, and JE and their receptor 
CXCR2 are also elevated following infection (74).  Of these mediators, TNF-α appears to 
be the most critical during P. aeruginosa pneumonia, as inhibition of TNF-α impairs 
neutrophil recruitment to the lung and bacterial clearance (75-77).  It has also been 
reported that IFN-γ and granulocyte-colony stimulating factor (G-CSF) may enhance 
TNF-α production in the lung to increase phagocytosis and clearance of P. aeruginosa 
(78).     
 
Cellular Mediators 
AMs and Monocytes 
 Macrophages are mononuclear, phagocytic cells and mature from monocytes that 
migrate from the blood stream into the tissues (79).  Macrophages are the largest 
phagocyte population in the alveolar space and interstitium of uninfected lungs (3, 80).  
Alveolar macrophages make up to 95% of immune cells present in the submucosal layer 
of the alveolar space.  Consequently, AMs are the first cellular line of defense against 
inhaled pathogens and are critical in the recognition and clearance of both opsonized and 




mediators to recruit immune effectors (such as neutrophils and monocytes) and to 
coordinate immune responses (3, 6).   
AM  and monocyte recognition and clearance of bacterial pathogens invading 
lung is a complex process involving several types of cell surface receptors and 
coordinating intracellular signaling events.  Receptors involved in AM phagocytic uptake 
of non-opsonized particles include: class A scavenger receptors and mannose receptors 
(81).  Additionally, bacterial pathogens opsonized by serum proteins, such as IgG or 
complement, are phagocytosed via FcγRs and complement receptors respectively on 
phagocytes (60, 82).  TLRs expressed on AMs are also important for induction of 
proinflammatory mediator production to enhance immune responses (3, 5).  Once 
pathogens are recognized and phagocytosed by AMs, various enzymatic and oxidative 
microbial killing mechanisms are activated to begin pathogen degradation (80). 
 
Neutrophils 
 Neutrophils are polymorphonuclear phagocytes and the primary granulocytes in 
the blood stream (83).  Neutrophils are the first immune cells recruited to sites of 
infection and injury in response to chemokine production and the presence of 
complement proteins, such as C5a (5, 6, 84).  Once at the site of infection, neutrophils are 
activated by the proinflammatory milieu to phagocytose and kill ingested bacterial 
pathogens (85).  Neutrophils are also capable of producing cytokines and chemokines for 
further recruitment and activation of other innate immune cells (3).  The neutrophil 
lifespan is short, and following clearance of bacterial pathogens, neutrophils must 




immune resolution and tissue repair (3, 6).  Therefore, excessive neutrophil recruitment 
combined with any delay in neutrophil death can lead to increased production of 
neutrophil-derived antimicrobial factors that may damage tissues.  In sites such as the 
lung, this can lead to conditions such as pulmonary edema and can increase the risk for 
bacteremia and sepsis (3, 6).    
 
AECs 
 AECs provide a physical barrier to inhaled pathogens and are the main structural 
cells involved in primary host defense against inhaled pathogens.  AECs express a 
number of TLRs, and in response to TLR and cytokine signaling, AECs are capable of 
producing β-defensin; proinflammatory cytokines, such as IL-6 and IL-1β; and 
chemokines, such as IL-8 for neutrophil recruitment (3, 86-88).  Ultimately, production 
of these mediators is thought to activate lung phagocytes and assist in the coordination of 
immune responses.  It is reported that conditioned medium from type II AECs enhances 
phagocytosis and bactericidal ROS production in AMs (89). 
 
Lymphocytes 
 Innate immune responses are effective in clearing acute bacterial lung infections.  
However, B- and T-cell antigen-specific immune responses in the lung are necessary for 
clearing chronic infections as well as infections caused by certain encapsulated bacteria, 
viruses, and intracellular pathogens surviving in AMs (4).  For example, complement 
activation and FcγR-mediated phagocytosis of IgG-opsonized pathogens employ antigen-




roles for T cells expressing NKG2D receptors and CD1d-restricted T cells have also been 
examined in murine models of P. aeruginosa pneumonia.  Deficient expression of CD1d 
or blockade of NKG2D inhibits neutrophil recruitment and bacterial clearance during P. 
aeruginosa lung infection (90, 91).  Additionally, AM production of IL-12 is known to 
promote T helper-1 cell responses, which in turn induce IFN-γ production for AM 
activation and promotion of B cell antibody-mediated immune responses (4).   
 
Phagocytosis and Intracellular Bacterial Killing 
Opsonic Phagocytosis 
 During infection, various proteins have been identified in the opsonization of P. 
aeruginosa for phagocytic uptake by AMs, monocytes, and recruited lung neutrophils.  
These opsonins primarily include IgG and complement proteins.  Complement 
opsonization plays an important role in phagocytosis of P. aeruginosa during acute 
infections, while chronic or repeated infection with P. aeruginosa may involve 
opsonization with IgG. 
 IgG opsonization of specific-antigen generates an immune complex that is 
recognized by various FcγR on the surface of phagocytes (92).  FcγR can have 
stimulatory (FcγRI, FcγRIII, and FcγRIV) and inhibitory (FcγRII) functions, and the net 
effect on phagocytosis and cytokine induction is determined by the relative expression of 
these receptors (93).  Engagement of stimulatory FcγR with IgG-opsonized pathogen 
initiates intracellular signaling events that drive cytoskeletal rearrangement, phagocytic 




(NADPH) oxidase assembly.  On the other hand, such signaling events are inhibited 
following engagement of inhibitory FcγR (94, 95). 
Activation of stimulatory FcγR induces phosphorylation of tyrosine residues on 
the cytoplasmic tail of the receptor.  This phosphorylation event allows for clustering of 
Src tyrosine kinases, Lyn and Hck, which phosphorylate other tyrosine residues that are 
bound by Syk kinase (94, 95).  Syk kinase is critical for phosphorylation and activation of 
phosphatidylinositol 3-kinase (PI3K).  Once activated PI3K converts PI-4,5-P2 (PIP2) 
into the key second messenger PI-3,4,5-P3 (PIP3) (95).  PIP3 can then bind to the 
pleckstrin homology domain of effectors downstream of the PI3K signaling pathway and 
mediate their activation.  PIP3 interactions with Vav, Rac, and Arf are reported to mediate 
NADPH oxidase assembly and phagocytic uptake (94, 95).   PI3K-mediated activation of 
other effectors, such as AKT, leads to phosphorylation of caspases and transcription 
factors which regulate cell proliferation, metabolic changes, and survival (96). 
During lung infection, complement-mediated phagocytosis of P. aeruginosa is 
reported to occur via activation of the alternative pathway and engagement of C3 
opsonized P. aeruginosa with CR3 (82).  To mediate phagocytosis of complement-
opsonized pathogens, phagocytes must be activated by IFNγ, C5a, or FcγR 
engagement/signaling (82).  Once activated, Src family kinases are recruited to the 
cytoplasmic tail of the CR and phosphorylate proteins which activate downstream 
effectors (such as PI3K, Vav, and AKT) and mediate cytoskeletal rearrangement, 
phagocytosis, and cytokine gene transcription.  CR3 may play additional roles in 
phagocytosis of P. aeruginosa (82).  CR3  has been reported to work together with 




(97).  It is also speculated that SP-D opsonized P. aeruginosa may also bind CD14/TLR4 
to mediate phagocytosis (82). 
 
Non-opsonic Phagocytosis 
AM phagocytosis of non-opsonized particles is critical for maintaining the 
sterility of the lower airways and clearance of bacterial pathogens early in infection.  
Several groups of receptors have been identified in the recognition of non-opsonized 
pathogens including: scavenger receptors, mannose receptor, asialoglycoprotein receptor, 
vitronectin receptor, CD48, CD14, CD44, and β-glucan receptor (81, 98).  Although 
accompanying signaling mechanisms have not been fully described, it has been reported 
that inhibition of PI3K, tyrosine kinases, and ERK diminishes phagocytosis of non-
opsonized particles (99).   
Specific receptors involved in non-opsonized phagocytic clearance of P. 
aeruginosa by macrophages in the lung have not been identified. In monocytes, however, 
the mannose receptor is known to bind the mannose-rich cell surface of P. aeruginosa to 
facilitate its phagocytic uptake as well as synergize with TLR2 to induce TNF-α 
production (100).  CD44-mediated phagocytosis has  recently been shown to occur via 
interaction with hyaluronan coated-particles.  It is speculated that phagocytosis of P. 
aeruginosa may be mediated via CD44 receptor binding, given that the cell surface of P. 
aeruginosa is rich in hyaluronic acid (98).  Class A scavenger receptors, such as SRA-I/II 
and macrophage receptor with collagenous structure (MARCO), are additional cell 




pathogens (81); however, no scavenger receptors have been identified in the specific-
binding and uptake of P. aeruginosa. 
 
Intracellular Bacterial Killing 
 Bacterial killing is a well described host defense mechanism in lung phagocytes. 
Following phagocytic uptake, pathogens are enclosed in an intracellular compartment 
called the phagosome.  The phagosome then undergoes maturation whereby the cellular 
machinery used to mediate killing of microbial cargo is activated and assembled (85).  
The first stage in maturation involves fusion of the phagosome with an early endosome, 
which is relatively acidic at pH 6.0.  This is followed by fusion with late endosomes at 
pH 5.5 and finally the lysosome at pH 5 (and lower) to form the phagolysosome (85).  In 
neutrophils, an additional fusion event also occurs with secretory vesicles and granules 
which are rich in antimicrobial peptides such as lactoferrin.  Following phagosome 
maturation, proteolytic enzymes and hydrolases become activated by the low pH to 
degrade pathogens (101, 102).  Additionally, ROS, which degrade pathogen surfaces, are 
formed by NADPH oxidase during respiratory burst.  NADPH generation of ROS 
involves the transfer of one electron to molecular oxygen, generating a superoxide anion 
that is converted to various reactive oxygen metabolites (85).   
 
Defective Pulmonary Host Defense Post-HSCT 
 During the post-engraftment phase, the risk for infectious complications 
significantly decreases primarily due to reestablishment of the immune system with 




can persist for many patients, despite immune reconstitution (8, 10, 30).   In particular, 
impaired pulmonary innate immune function has been reported in patients up to a year or 
more post-HSCT and is associated with increased risk for infectious pneumonia (17, 27, 
103).  
 Multiple defects have been reported in the host defense function of AMs from 
BMT patients.  Winston and colleagues conducted a study among twelve healthy 
individuals and seven patients who had successfully undergone allogeneic BMT for the 
treatment of either acute leukemia or aplastic anemia.  All BMT patients were no longer 
on immunosuppressive drug therapy (104).  Compared to healthy subjects, BMT patients 
displayed normal leukocyte composition in BAL fluid, and AMs constituted the majority 
of leukocytes counted.  Chemotaxis, phagocytosis and killing in AMs were also assessed 
in patients two, three, six and fourteen months post-BMT.  Two to four months post-
BMT, patients showed substantial decreases in all host defense mechanisms tested.  At 
six and twelve months post-BMT, AM phagocytosis and killing were improved but still 
significantly decreased relative to control subjects.  AM chemotaxis at these later time 
points remained significantly impaired in BMT patients relative to controls.  
Interestingly, peripheral blood monocytes from these BMT patients displayed normal 
host defense functions, suggesting the possibly of a lung or cell-type specific defect 
(104).  
Similarly, allogeneic BMT patients display impaired neutrophil chemotaxis, ROS 
production, phagocytosis, and killing.  One study reported defects within the first few 
months of BMT that persisted in the majority of patients up to a year post-BMT (105).  




complete immune reconstitution in HSCT patients.  However, the presence of GVHD and 
use of cyclosporine A immunosuppressive therapy may have had a significant impact on 
immune function in these patients, aside from possible transplant-related immune defects.   
Therefore, studies employing syngeneic and autologous HSCT are necessary to assess the 
impact of HSCT alone on immune function, without the confounding effect of GVHD or 
use of exogenous immunosuppressive therapies. 
 
Murine Model of P. aeruginosa Pneumonia Post-BMT 
Our laboratory developed a mouse model of syngeneic BMT to determine the 
effect of conditioning and reconstitution alone on pulmonary innate immune function and 
the susceptibility of the host to P. aeruginosa pneumonia (106).  In our model, C57BL/6 
(B6) mice were given a fractionated dose of 13 Gy TBI and infused by tail vein injection 
with 5 x 10
6
 whole bone marrow cells and 1 x 10
6
 purified splenic T cells from B6 
donors.  1 week following BMT, 99% of neutrophils were donor-derived and by week 3 
post-BMT, mice displayed normal numbers of all immune cells and approximately 90% 
of AMs were of donor origin (106).   
Despite complete immune reconstitution, BMT mice displayed increased 
susceptibility to P. aeruginosa pneumonia (106).   Between BMT and non-transplant 
control mice given a sublethal dose of P. aeruginosa, BMT mice displayed increased 
bacterial burden in the lung and increased dissemination of P. aeruginosa to the blood 
relative to control mice.  The increase in bacterial load in the lungs and blood of BMT 
mice was associated with decreased host defense function of both AMs and recruited 




showed reduced phagocytosis and bacterial killing.  Recruited lung neutrophils 
phagocytosed both opsonized and non-opsonized particles at levels similar to control 
neutrophils; however, bacterial killing in BMT lung neutrophils was markedly reduced 
relative to control.  Furthermore, diminished production of key proinflammatory 
mediators, such as TNF-α and cys-LTs, was observed in BMT AMs.  These data suggest 
that the procedure of transplant can have a profound effect on pulmonary immune 
function and host defense against opportunistic pathogens, despite complete immune 
reconstitution (106).   Although the cause may be multifactorial, we have since identified 
the immunosuppressive lipid mediator, PGE2, as a factor induced following transplant 
that mediates this impairment in pulmonary host defense (68).   
 
PGE2 
PGE2 is a member of the eicosanoid family of immune active lipid mediators 
which primarily includes PGs and LTs (72).  Eicosanoids are generated from cytosolic 
phospholipase A2 cleavage of cell membrane-derived phospholipids into arachidonic 
acid (Fig. 1.1).  Cyclooxygenase (COX)-1 and -2 proteins in the cytoplasm are the 
sentinel enzymes involved in the conversion of arachidonic acid into the PG intermediate, 
PGH2, from which the prostaglandins PGA2, PGD2, PGE2, PGF2, and PGI2 are derived.  
As with all eicosanoids, PGs bind to GPCRs on the cell surface to modulate a both pro- 
and anti-inflammatory responses (72).   
PGE2, in particular, is produced by both leukocytes and structural cells and binds 
to the PG receptors, E prostanoid (EP) 1 through EP4 (107).  PGE2 binding to EP2 and 




messenger cyclic adenosine monophosphate (cAMP).  EP2 and EP4 are coupled to 
cAMP stimulatory Gs proteins.  Engagement of these GPCRs activates the membrane-
bound enzyme adenylyl cylcase (AC), which converts adenosine triphosphate (ATP) into 
cAMP (108).  Increases in intracellular cAMP activates downstream effectors that inhibit 
proinflammatory cytokine production, bacterial killing, and phagocytosis (109).  The 
remaining PGE2 receptors, EP1 and EP3, have different functions.  EP1 is coupled to Gq, 
which increases intracellular calcium levels for induction of proinflammatory responses, 
and EP3 is coupled to the AC inhibitor Gi (72). 
 
 
Figure 1.1: The eicosanoid signaling pathway 
Eicosanoids are generated from cytosolic phospholipase A2 cleavage of cell membrane-
derived phospholipids into arachadonic acid.  Cyclooxygenase (COX)-1 and -2 proteins 
in the cytoplasm are the sentinel enzymes involved in the conversion of arachidonic acid 
into the PG intermediate, PGH2, from which the prostaglandins PGA2, PGD2, PGE2, 
PGF2, and PGI2 are derived.  5-lipoxygenase and 5-lipoxygenase activating protein 





PGE2-Mediated Suppression of Pulmonary Host Defense Post-BMT 
In the setting of HSCT, PGE2 levels are significantly elevated and play a major 
role in reduced immune function and host defense against opportunistic pathogens (68, 
110).   Overproduction of PGE2 following HSCT was first reported by Cayeux and 
colleagues (110).  In the study, 14 patients with acute myeloid leukemia, Hodgkin’s 
lymphoma, or non-Hodgkin’s lymphoma were given an autologous BMT following a 
conditioning regimen of either high-dose chemotherapy alone or combined 
TBI/chemotherapy.  Following BMT, plasma PGE2 levels were increased in all patients 
between 3- and 10-fold relative to control subjects.  This increase was observed 
irrespective of the type of conditioning regimen used to ablate the host bone marrow.  
The increase in plasma PGE2 levels lasted between 30 to 60 days post-BMT before 
returning to baseline levels (110).  The cause of elevated PGE2 levels post-BMT has yet 
to be determined but may involve release of PGs from damaged epithelial cell barriers 
following conditioning. 
 In our murine model of syngeneic BMT, we have demonstrated that PGE2 is 
elevated in the lung (68).  When mice were fully donor-cell reconstituted 3 weeks post-
BMT, PGE2 production was increased approximately 2.8-fold in lung homogenates, 2.7-
fold in AECs, 125-fold in AMs, and 10-fold in recruited lung neutrophils.  Furthermore, 
EP2 and EP4 gene expression was increased approximately 2- and 4-fold respectively in 
recruited lung neutrophils from BMT mice relative to control mice.  EP2 was elevated 
approximately 3-fold in BMT AMs relative to control AMs; however, expression of EP4 




 In our BMT model, elevated production of PGE2 in the lung directly contributes 
to the impairment of innate immune function and host defense against P. aeruginosa 
pneumonia (68).  Pharmacologic inhibition of prostaglandins, using the COX-2 inhibitor 
indomethacin, restored BMT AM phagocytosis and killing of IgG and non-IgG opsonized 
targets and enhanced phagocytosis in control AMs.  Similarly, using COX-2 +/- mice as 
bone marrow donors also restored BMT AM phagocytosis.  The EP2 antagonist, AH-
6809, also conferred a similar effect suggesting a role for EP2 signaling in the inhibition 
of BMT AM phagocytosis.  Interestingly, indomethacin also had a profound impact on 
host defense against P. aeruginosa lung infection.  In BMT mice, in vivo treatment with 
indomethacin restored clearance of P. aeruginosa, prevented dissemination of P. 
aeruginosa to the blood, and restored production of cys-LTs in the lung (68).  These data 
suggest a critical role for PGE2 and potentially other prostaglandins in impaired 
pulmonary host defense post-BMT.  However, the mechanism for this inhibition remains 
unclear.  Moreover, it is important to determine whether the elevation we observe in 
PGE2 production and its effect on immune function in our model would also occur 
following the use of more clinically relevant conditioning regimens, such as high dose 
chemotherapy. 
 
Mechanisms of PGE2-Mediated Immunosuppression 
 The mechanism of PGE2-mediated inhibition of host defense in leukocytes 
generally involves binding of PGE2 to EP2/EP4 and activation of AC to induce cAMP 
production (107, 109).  cAMP is then able to interact with two downstream effectors, 




inhibit inflammatory mediator production, microbial killing, and phagocytosis (Fig. 1.2) 
(109). 
 
Figure 1.2: PGE2-mediated inhibition of host defense   
PGE2 engagement of either EP2 or EP4 activates AC to induce cAMP production.  cAMP 
is then able to interact with two downstream effectors, PKA and EPAC-1, which inhibit 
inflammatory mediator production, microbial killing, and phagocytosis. 
 
cAMP modulates production of a variety of inflammatory mediators via 
interactions with PKA (111).  Although a precise mechanism has not been determined, 
cAMP interaction with PKA is thought to attenuate activation of NFκ-B and inhibit NF-
κB-mediated transcription of proinflammatory mediators (112, 113).  Key mediators 
inhibited by PGE2 in this manner include: TNF-α, IL-12, LTB4, and MIP-1 (114-116).  




production of the immunosuppressive cytokine, IL-10, and expression of the negative 
regulator of cytokine signaling, suppressor of cytokine signaling (SOCS)-3 (114, 117). 
Elevated cAMP production can also inhibit opsonized and non-opsonized 
phagocytosis.  Phagocytic clearance of myelin, the protein which surrounds axons, is 
inhibited by increased cAMP production in a PKA- and EPAC-1-dependent manner 
(118).  FcγR-mediated phagocytosis in monocyte-derived macrophages is also regulated 
by PKA and EPAC-1 (119); however, recent work has also shown that PGE2-mediated 
inhibition of FcγR phagocytosis in AMs is specifically regulated by EPAC-1 (120).  It 
was shown that EPAC-1-specific inhibition of AM FcγR-mediated phagocytosis involves 
EPAC-1 activation of the tyrosine phosphatase src homology 2-containing inositol 
phosphatase (SHIP)-1.  SHIP-1 in turn activates phosphatase and tensin homolog on 
chromosome 10 (PTEN), which negatively regulates FcγR signaling (120). 
Intracellular microbial killing mechanisms are also suppressed by PGE2-mediated 
increases in cAMP.  cAMP activation of PKA can inhibit phagocyte release of ROS 
following stimulation with IgG-coated particles (121-123).  In AMs, activation of either 
PKA or EPAC-1 inhibits hydrogen peroxide production following infection with K. 
pneumoniae (124).  The mechanism for this suppression of ROS production has not been 
defined but is associated with reduced activation NADPH oxidase (109, 123).  Roles 
remain conflicting for PGE2 activation of the cAMP signaling cascade in the inhibition of 
nitric oxide (NO) production and phagolysosome maturation.  In hepatic macrophages, 
increased cAMP levels inhibit activation of NO synthase (125); however, several studies 




Similarly, cAMP has been shown to inhibit phagolysosome maturation and acidification 
in some studies (129) and promote phagolysosomal acidification in others (130). 
 Taken together, PGE2-mediated increases in cAMP have a number of effects on 
host defense in phagocytes.  Although roles for PKA and EPAC-1 have been established 
in PGE2-mediated suppression of host defense, specific roles for molecules downstream 
of PKA and EPAC-1 have yet to be delineated.  Elucidation of these signaling pathways 
would provide greater insight into the mechanism behind impaired host defense in 
settings where PGE2 is elevated, such as HSCT.  Currently, our laboratory has focused on 
potential roles for the negative regulator of IL-1R/TLR signaling, IRAK-M, and the 




 In our model of BMT, AMs display impaired production of the proinflammatory 
cytokine, TNF-α (106).  Numerous molecules have been identified in the negative 
regulation of pathways, such as TLR/IL-1R signaling, that induce production of 
proinflammatory mediators.  A list of these molecules and their known inhibitory 
functions are reviewed extensively by Wang and colleagues (131). Of particular interest 
is the potential role for the negative regulator of TLR signaling, IRAK-M, in impaired 
AM host defense post-BMT. 
Human IRAK-M was first characterized in 1999 by Wesche and colleagues (132).  
The IRAK-M gene is located on human chromosome 12 at position 12q14.1 – 12q15 and 




N-terminal death domain for MyD88 TIR-TIR interaction and a central serine/threonine 
kinase domain consisting of 12 subdomains.  However, only IRAK-1 and -4 contain a 
functional catalytic site with a critical aspartate residue in kinase subdomain VI (61).  
This residue is an asparagine and serine in IRAK-2 and -M respectively, rendering these 
kinases inactive.  The murine IRAK-M homologue shows 71% sequence identity to 
human IRAK-M and has similar limitations in kinase activity (133).  It is now known that 
IRAK-M negatively regulates TLR/IL-1R signaling by binding the MyD88 adaptor 
complex (61).  
Human IRAK-M expression is generally confined to monocytes and 
macrophages, and its expression is induced during macrophage maturation and TLR/IL-
1R signaling (132, 134).  Tissue-specific mRNA expression in human brain, liver, 
thymus and small intestine has not been detected.  However, recent studies by Balaci and 
colleagues show IRAK-M protein expression in lung epithelial cells of asthmatic patients 
(135).  This is consistent with murine studies examining IRAK-M expression in the lung, 
where AECs express IRAK-M under both basal and inflammatory conditions (136, 137). 
Murine IRAK-M has a broader expression pattern compared to human IRAK-M.  
Murine IRAK-M has been detected not only in monocytes and macrophages but also in 
neutrophils (138), the NIH 3T3 fibroblast cell line (133), B cells (139), and epithelial 
cells of the intestine, lung, and intrahepatic bilary ducts (136, 137, 140, 141).  
Furthermore, IRAK-M mRNA has been detected in various tissues, with highest 
expression in the thymus and liver and relatively lower expression levels in the heart, 
brain, spleen, and kidney (133).  It is not clear whether this is related to the presence of 





IRAK-M Regulation of TLR/IL-1R Signaling Pathways 
IRAK-M can heterodimerize with IRAK-1 or -2 and bind both MyD88 and tumor 
necrosis factor receptor associated factor 6 (TRAF6) (61).  Upon TLR/IL-1R ligand 
engagement and formation of the MyD88 adaptor complex, IRAK-M is thought to bind 
MyD88/IRAK-4 and inhibit IRAK-4 phosphorylation of IRAK-1 (Fig 1.3).  This 
prevents formation of TRAF6/IRAK-1 complexes, which initiate IκB kinase (IKK) and 
mitogen activated protein (MAP) kinase signaling pathways for activation of nuclear 
factor κ B (NF-κB) and activator protein (AP-1) transcription factors (134).  This role for 
IRAK-M in the negative regulation of TLR/IL-1R signaling was established in 
experiments demonstrating that transfection of MyD88 and IRAK-1 into 293T cells 
increases IRAK-1 phosphorylation (134).  However, transfection of IRAK-M along with 
MyD88 and IRAK-1 increases the amount of unphosphorylated IRAK-1 relative to 
phosphorylated IRAK-1.  Furthermore, overexpression of IRAK-M diminishes formation 
of IRAK-1/TRAF6 complexes (134).   Exactly how IRAK-M inhibits NF-κB and AP-1 





Figure 1.3: IRAK-M-mediated inhibition of TLR signaling 
Upon TLR ligand engagement and formation of the MyD88 adaptor complex, IRAK-M 
binds MyD88/IRAK-4 to inhibit IRAK-4 phosphorylation of IRAK-1.  This prevents 
formation of TRAF6/IRAK-1 complexes, which initiate IKK and MAP kinase signaling 
pathways for activation of the transcription factors NF-κB and AP-1.   
 
IRAK-M in Impaired Pulmonary Host Defense Against P. aeruginosa 
 IRAK-M expression is regulated by a number of molecules, including 
endogenous and exogenous soluble factors as well as cell surface and intracellular 
signaling molecules.  A well characterized group of cell surface molecules known to 
induce IRAK-M expression is TLRs.  Induction of IRAK-M expression via TLR 
activation serves as a means to induce tolerance to subsequent TLR stimulus and 




are induced within 3 and 6 hours respectively following stimulation with LPS, a 
component of bacterial cell walls that activates TLR4 (134, 142).  This is a key feature of 
the induction of endotoxin tolerance in monocytes and macrophages during sepsis to 
prevent lethal cytokine storm.  Deactivation of macrophages during sepsis, however, 
generates a state of immunosuppression that renders patients susceptible to secondary 
infections such as pneumonia (143).   
One particular study demonstrated that in mice, the absence of IRAK-M 
expression can overcome the immunosuppressive stage of sepsis and promote protective 
immune responses against secondary challenge with P. aeruginosa (144).  Deng and 
colleagues found that following sepsis, AMs had increased  IRAK-M mRNA expression 
and decreased TNF-α  production relative to sham controls (144).  In the absence of 
IRAK-M, however, AMs from septic mice displayed enhanced TNF-α production.   
Following secondary challenge with P. aeruginosa lung infection, IRAK-M -/- septic 
mice displayed decreased mortality, improved bacterial clearance, elevated production of 
proinflammatory cytokines and chemokines, and increased neutrophil recruitment to the 
lung (144).  Thus, deficiency in IRAK-M can improve the ability of septic mice to 
resolve secondary infection with P. aeruginosa.  Similar enhancement in bacterial 
clearance was also observed in IRAK-M -/- mice compared to WT mice 72 h following 
oral challenge with  Salmonella typhimurium (134).  Taken together, these data suggest 
possible roles for IRAK-M in the suppression of lung phagocyte host defense against P. 
aeruginosa following BMT.  Whether overproduction of the immunosuppressive lipid 







 Following BMT, AMs display reduced ability to phagocytose both opsonized and 
non-opsonized targets (68, 106).  PTEN is a known inhibitor of signaling pathways that 
facilitate both opsonized and non-opsonized phagocytosis (145), and PGE2 activation of 
the cAMP signaling cascade has previously been shown to induce PTEN phosphatase 
activity (120).  Therefore, PGE2-mediated activation of PTEN may be a potential 
mechanism for the inhibition of phagocytosis and other host defense mechanisms in BMT 
AMs. 
 The PTEN gene is located on human chromosome 10q23 and encodes a 403 
amino acid protein.  PTEN is composed of four major domains: a catalytic phosphatase 
domain, a C2 domain, and an N- and C-terminal domain (146).  The C2 domain and the 
N-terminal sequence are important for PTEN binding to membrane lipids, while the C-
terminal domain is necessary for protein-protein interaction with scaffolding proteins 
(147, 148).  The catalytic domain of PTEN is similar in structure to protein tyrosine 
phosphatases and may act on protein substrates including FAK and PTEN itself (149, 
150).  However, PTEN is best characterized for its dephosphorylation of the lipid second 
messenger, PIP3 (146).   
 PTEN phosphatase activity is regulated by a number of post-translational 
modifications which contribute to its subcellular localization, protein-protein interactions, 
stability, and phosphatase activity (146).   PTEN stability depends on interaction of 




PTEN cleavage by caspase 3 (151).  PTEN  also contains two PEST motifs which subject 
PTEN to ubiquitin-regulated proteasomal degradation (146).  Oxidation of specific 
residues is also known to reversibly inactivate PTEN and promote PI3K signaling (152).  
Lastly, phosphorylation of various tyrosine and serine/threonine residues regulates PTEN 
activity (146).  The serine/threonine residues involved in the regulation of PTEN are well 
described; however, the specific tyrosine residues involved in PTEN inhibition have yet 
to be identified. 
 
PTEN Inhibition of PI3K/PIP3 Signaling 
 PTEN dephosphorylation of PIP3 inhibits activation of several effector molecules 
in the PI3K/PIP3 signaling pathway (Fig. 1.4).  PI3K/PIP3 signaling mediates key cellular 
functions such as growth, survival, cell migration, cell differentiation, and metabolism 
(153).  The primary immune functions regulated by PI3K/PIP3 signaling include: 
phagocytosis, phagosome maturation, and NADPH oxidase assembly and activation.  
PI3K is activated in response to engagement of receptor tyrosine kinases at the cell 
surface, including FcγR (95).  PI3K is then able to phosphorylate PIP2 at the cell 
membrane, converting it into PIP3.  PTEN then antagonizes PI3K activity by 





Figure 1.4: PTEN-mediated inhibition of PI3K/PIP3 signaling. 
PI3K is activated in response to engagement of receptor tyrosine kinases at the cell 
surface, including FcγR.  PI3K is then able to phosphorylate PIP2 at the cell membrane, 
converting it into PIP3.  PTEN then antagonizes PI3K activity by dephosphorylating PIP3 
and converting the lipid substrate back to PIP2.  PIP3 activates multiple downstream 
effectors that modulate host defense in leukocytes. 
 
PTEN and Impaired Host Defense in Phagocytes 
 PTEN expression is ubiquitous and can be detected early in development.  
However, examining the role of PTEN in the regulation of immune responses requires 
targeted or conditional ablation of PTEN expression, due to the embryonic lethality of 
PTEN -/- mice (154).  As a result, several studies have employed conditional knockout 




immune cell compartments. Use of myeloid-specific PTEN knockout mice, in particular, 
has provided much insight in the role of PTEN in the negative regulation of host defense 
functions in macrophages and neutrophils.   
 A role for PTEN in the regulation of FcγR-mediated phagocytosis and TLR 
signaling was first described in 2004 by Cao and colleagues (145).  In this study, 
myeloid-specific ablation of PTEN in mice enhanced peritoneal macrophage FcγR-
mediated phagocytosis and production of proinflammatory cytokines such as TNF-α and 
IL-6.  Furthermore, their results suggested that PI3K activity was enhanced in the 
absence of PTEN, leading to AKT-mediated suppression of TLR4 signaling (145).  
Results of this study have been corroborated by several reports demonstrating enhanced 
tissue-specific macrophage and neutrophil function in myeloid-specific PTEN -/- models 
(155-158).  Taken together, these data demonstrate that the negative regulation of PI3K 
by PTEN profound has effects on multiple host defense functions in macrophages and 
neutrophils.  Furthermore, since PGE2-mediated activation of the cAMP signaling 
cascade is known to increase PTEN activity (120), it is plausible that overproduction of 
PGE2 in the lung following BMT may lead to increased PTEN activity in lung 
phagocytes, ultimately resulting in impaired phagocytosis, bacterial killing, and 
proinflammatory cytokine production. 
 
Concluding Remarks 
 HSCT provides significant therapeutic benefit to patients suffering from various 




the success of this therapy is hampered by infectious complications arising from delayed 
immune reconstitution and ongoing impairment in immune function.  Our studies have 
identified overproduction of PGE2 in the lung as a major contributor to impaired 
pulmonary host defense following BMT.   However, it is not known whether PGE2-
mediated suppression of pulmonary host defense that is observed in our model is specific 
to the type of conditioning regimen used to ablate the host HSC.  Therefore, it is critical 
to establish whether use of chemotherapy, which is a more commonly used conditioning 
regimen for bone marrow ablation in patients, would induce similar suppression of 
pulmonary host defense.  Moreover, it will also be critical to establish a mechanism for 
PGE2-mediated inhibition of pulmonary host defense in BMT mice and to identify 







CHAPTER 2: Materials and Methods 
Animals 
Wild type C57BL/6 (B6Ly5.1; CD45.2) mice were obtained from Jackson 
Laboratory (Bar Harbor, ME). B6Ly5.2 (CD45.1) mice were purchased from the Fredrick 
Cancer Research Facility (Fredrick, MD).  IRAK-M-deficient mice bred on a B6 
background have previously been described (134) and were bred at the University of 
Michigan.  Conditional PTEN KO (PTEN
loxP/loxP
) and myeloid-specific Cre mice were 
obtained from The Jackson Laboratory (Bar Harbor, Maine).  Myeloid-specific PTEN 
KO mice were generated by breeding as previously described (158).  For all experiments 




 mice were used as WT 




 mice were used as PTEN conditional 
knockout (CKO) bone marrow donors.  Mice were housed under specific pathogen-free 
conditions and were monitored daily by veterinary staff.  All mice were euthanized by 
CO2 asphyxiation. The University of Michigan Committee on the Use and Care of 
Animals approved these experiments 
 
Bone marrow transplantation 
Mice were given a syngeneic BMT.  For our conditioning regimen studies, mice 
were treated as follows:  1) TBI + T mice received 5 x 10
6
 whole bone marrow (BM) 
cells + 1 x 10
6






marrow cells following 13 Gy TBI; 3) Dual chemo mice received 5 x 10
6
 bone marrow 
cells following conditioning with 25 mg/kg bulsufan x 4 days + 100 mg/kg 
cyclophosphamide x 2 days + 1 day rest; 4) Cyclo mice received 5 x 10
6
 bone marrow 
cells following conditioning with 100 mg/kg cyclophosphamide x 2 days + 1 day rest; 5) 
Bus Lo mice received 5 x 10
6
 bone marrow cells following conditioning with 50 mg/kg 
busulfan x 1 day + 1 day rest; 6) Bus Hi mice received 5 x 10
6
 bone marrow cells 
following conditioning with 25 mg/kg bulsulfan x 4 days + 1 day rest.  Mice given TBI in 
our conditioning regimen studies were exposed to a 
137
Cs source.  For our studies 
examining roles for IRAK-M and PTEN post-BMT, recipient mice received 13 Gy of 
TBI (orthovoltage x-ray source) split in two fractions, three hours apart.  For our 
conditioning regimen studies, B6Ly5.2 mice (CD45.1) were used as bone marrow donors 
for B6Ly5.1 (CD45.2) recipients.    For all studies, bone marrow cells and splenic T cells 
were harvested from donor mice and resuspended in serum-free media (SFM; DMEM, 
0.1% BSA, 1% penicillin-streptomycin, 1% L-glutamine, 0.1% amphotericin B).  Donor 
cells were administered by tail vein injection into recipient mice.  All experiments were 
performed 3-6 weeks post-BMT when mice were fully donor-cell reconstituted (68, 159).  
Mice were maintained on acidified water (pH 3.5) for the first 21 days post-BMT. 
 
P. aeruginosa PAO1 preparation and FITC-labeling 
P. aeruginosa PAO1 stock was grown in tryptic soy broth (Difco; BD, Sparks, 
MD), and the culture concentration was determined via absorbance measurements as 
previously described (106).  For FITC-labeling, a P. aeruginosa culture was centrifuged 









 CFU/mL in 0.1 M NaHCO3 (pH 9.2).  0.2 mg/mL FITC 
(Sigma, St. Louis, MO) in DMSO was added to heat-killed P. aeruginosa and allowed to 
incubate in dark for 1 hour on rocker at room temperature.  Following FITC-labeling, 
heat-killed P. aeurginosa were washed three times and resuspended in 1 mL sterile PBS.  
Aliquots were prepared and stored at -80ºC until use. 
 
Immune serum preparation and opsonization 
P. aeruginosa-specific immune serum was prepared from Wistar rats immunized 
with P. aeruginosa as previously described (160).  Immune serum was aliquoted and 
stored at -80°C until use.  For serum opsonization of FITC-P. aeruginosa, 1 x 10
8
 FITC-
P. aeruginosa were resuspended in 5% immune serum in PBS and incubated on a rotator 
for 1h at 37°C.  For serum opsonization of live P. aeruginosa, 1 x 10
8
 P. aeruginosa was 
resuspended in 5% immune serum in PBS and incubated on a rotator for 15 mins at 37°C.  
No complement heat-inactivation of immune serum was performed prior to opsonization 
of heat-killed or live bacteria. 
 
i.t. infection with P. aeruginosa 
A culture of P. aeruginosa was grown as described above, and an inoculum was 
prepared.  Mice were anesthetized and i.t. injected with 50 μL of inoculum to provide 
either a sublethal dose of 5 x 10
5
 CFU or a lethal dose of 1.5 x 10
6
 CFU as previously 





Quantification of bacterial burden in lung and blood 
Mice were euthanized 24 hours following i.t. infection with P. aeruginosa.  As 
previously described (68), whole lung and blood samples were collected from each 
mouse and bacterial burden of each specimen was assessed by performing a CFU assay. 
 
AM isolation and adherence purification 
AMs were harvested by bronchoalveolar lavage (BAL), counted, and adherence 
purified as previously described (159).  Where indicated, AMs were cultured overnight 
on 24-well tissue culture plates in the presence or absence of PGE2 (Cayman Chemicals, 
Ann Arbor, MI), forskolin (Sigma), indomethacin (Sigma) or vehicle (0.25% ethanol) in 
SFM or complete media (CM; DMEM, 10% FCS, 1% penicillin-streptomycin, 1% L-
glutamine, 0.1% amphotericin B).  Following treatment, samples were prepared as 
described below for real-time RT-PCR or Western blot analysis. 
 
IgG-sheep red blood cell FcγR stimulation assay 
AMs cultured overnight in CM were washed once with PBS and incubated at 
37°C in SFM for 20 mins.  Culture media in wells was then replaced with indomethacin 
(5 μM, 2h) or PGE2 (100 nM, 15 min) in SFM.  Subsequently, freshly IgG-opsonized or 
non-opsonized sheep red blood cells (SRBCs; MP Biomedicals, Solon, OH) were 




37°C.  Wells were then washed once with PBS on ice, and whole-cell lysates were 
prepared for Western blot analysis as described below. 
 
PTEN phosphatase activity assay 
PTEN was immunoprecipitated from control and BMT AM whole-cell lysates to 
assess in vitro lipid phosphastase activity as previously described (161).  Briefly, 200μM 
D-myoPIP3 (Echelon Biosciences) was incubated with PTEN immunoprecipitates for 30 
min to allow for dephosphorylation of PIP3.  The amount of PIP3-derived free phosphate 
released in each sample was determined by adding BIOMOL Green reagent to each 
sample and measuring the absorbance using a colormetric plate reader at 630 nm.  PTEN 
lipid phosphatase activity was quantified in each sample as relative absorbance to control 
samples. 
 
Neutrophil recruitment to lung and isolation 
 As previously described, neutrophils were recruited to the lung via i.t. injection of 
a 25 μg dose of P. aeruginosa-derived LPS (Sigma) and isolated by BAL 24 hours later 
(68).  Neutrophils comprised approximately 80% of all BAL cells at this time point in all 
groups. 
 




As reported previously (68, 162), BMT mice were injected intraperitoneally (i.p.) 
with a 100 μL dose of either 1.2 mg/kg indomethacin (Sigma) or 1% DMSO (vehicle) in 
sterile PBS.  24 hours following i.p. injection, AMs were harvested from mice by BAL 
and purified as described above.  
 
Total lung leukocyte preparation 
Whole lung samples were harvested from mice and collagenase digested as 
previously described (144) to isolate lung leukocytes.  For each sample, total viable cell 
number was counted on a hemacytometer by trypan blue exclusion. Where indicated, 
remaining cells were either stained for flow cytometry (as described below) to identify 
lymphocyte populations, or stained with modified Wright-Giemsa stain to determine the 




 Donor vs. host reconstitution of AMs was determined by flow cytometry using 
CD45.1-PE and CD45.2-FITC directly conjugated Abs purchased from BD/Pharmingen 
(San Diego, CA).  Following total lung leukocyte preparation described above, 1 x10
6
 
cells were stained using fluorochrome-conjugated antibodies against the cell surface 
markers CD45, CD4, CD8, CD19, NK1.1, TCRβ, (BD Pharmingen, San Jose, CA) 
following incubation with anti-CD16/CD32 (FcBlock, BD Pharmingen).  To enumerate 
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B cells were identified as CD19
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In vitro phagocytosis assay 
AMs isolated by BAL were plated at 2 x 10
5
 cells per well and cultured overnight 
in CM on a 96-well, flat-bottomed, half-area tissue culture plate (Costar, Corning, NY). 
The following day, wells were aspirated and replaced with 50 μL of SFM.  Where 
indicated, AMs were pretreated with or without 10 nM PGE2 for 15 mins (Cayman 
Chemicals, Ann Arbor, MI).  In some experiments, AMs were pretreated with or without 
100 nM bpV(pic) in SFM for 30 mins (EMD Chemicals, Gibbstown, NJ) to inhibit PTEN 
activity.  AMs were then incubated with either FITC-labeled E. coli using the Vybrant 
Phagocytosis Assay Kit according to manufacturers’ instructions (Invitrogen, Carlsbad, 
CA) or FITC-labeled heat-killed P. aeruginosa (prepared as described above) at 300:1 
MOI.  2 hours following incubation at 37ºC in dark, 50 μL of trypan blue (250 μg/mL in 
0.09 M citrate buffer solution; Sigma) was added to each well for 1 min to quench 
fluorescence of non-phagocytosed FITC-labeled bacteria.  AM phagocytosis of FITC-
labeled bacteria was measured using a microplate fluorimeter and expressed in arbitrary 
fluorescence intensity units as described previously (106, 163).  For possible differences 
in AM adherence to tissue culture plate, data were normalized for cell number using a 






Bacterial killing tetrazolium dye reduction assay 
AMs or neutrophils isolated by BAL were plated at 2 x 10
5
 cells per well in 
replicate on two 96-well tissue culture plates (one control and one experimental plate).  
Killing of P. aeruginosa was quantified using a tetrazolium dye reduction assay as 
described previously (165).  Briefly, phagocytes on the control plate were allowed only to 
phagocytose bacteria, while phagocytes on the experimental plate were permitted to both 
phagocytose and kill ingested bacteria.  After 5 hours incubation, the amount of surviving 
ingested bacteria was quantified using an MTT assay according to manufacturer’s 
instructions (Sigma).  Results were expressed as % surviving ingested bacteria = (A595 
control/A595 experimental)/ x 100%. 
 
Real-time RT-PCR 
Real-time RT-PCR was performed on an ABI Prism 7000 thermocycler (Applied 
Biosystems, Foster City, CA).  Gene-specific primers and probes were designed using 
Primer Express software (PE Biosystems, Foster City, CA) as previously published (68, 
144).  Sequences for all primers and probes used can be found in Table 2.1.  Each AM 
sample was pooled from 2-3 mice and was run in duplicate.  Average cycle threshold 
(CT) was determined for each sample and was normalized to β-actin.  Relative gene 





Table 2.1 Primers and probes used in real-time RT-PCR analysis 
 
 
Western blot analysis 
Whole-cell lysates of AMs or neutrophils were obtained by treating cells with 
RIPA buffer as previously described (144).  Protein concentration of lysates was 
determined by the Bio-Rad DC Protein Assay (Hercules, CA).  10 μg protein samples 
were electrophoresed in a 4-20% Tris-Glycine Novex Pre-Cast Gel (Invitrogen; Carlsbad, 
CA) and transferred to a nitrocellulose membrane.  Membranes were blocked for 1 hour 
at room temperature and probed with one of the following primary antibodies: rabbit anti-




IL); rabbit anti-cPLA2, rabbit anti-FLAP (Santa Cruz Biotechnology, Santa Cruz, CA); 
rabbit anti-COX-2, rabbit anti-PGES1, rabbit anti-PGES2, and rabbit anti-5-LO (Cayman 
Chemicals, Ann Arbor, MI); or mouse anti-phosho-Akt (Ser
473
) and rabbit anti-PTEN 
(Cell Signaling, Danvers, MA).   Primary antibody incubations were followed by goat 
anti-rabbit or anti-mouse IgG-HRP (Pierce) secondary antibody incubations.  Bands were 
visualized using chemiluminescence (SuperSignal West Pico Substrate; Pierce).  To 
assess total AKT protein levels relative to pAKT levels, membranes probed for pAKT 
were stripped, reblocked, and probed with mouse anti-AKT antibodies (Cell Signaling) 
according to manufacturer’s instructions.  To quantify protein expression, band intensity 
was measured using Image J Software available for download at 
http://rsbweb.nih.gov/ij/download.html. 
 
ELISA/enzyme-linked immunoassay (EIA) 
AMs were cultured overnight at 2 x 10
6
 cells per mL in a 96-well tissue culture 
plate, and supernatants were collected the following day for enzyme immunoassay (EIA).  
For cys-LT determination, AMs were cultured in SFM instead of CM, and lung 
homogenates were prepared using the SepPak procedure to isolate lipids prior to EIA 
analysis as previously described (166).  TNF-α production was measured using a DuoSet 
enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN).  
Production of PGE2,6-keto-PGF1α (a stable metabolite of PGI2), and  total cys-LTs 
(LTC4, LTD4, and LTE4) was measured by EIA (Cayman Chemical) according to 






For measurement of cAMP production, AMs were plated 5 x 10
5
 cells per well in 
CM overnight.  The following day, AMs were treated with 1 μM PGE2 in SFM for 15 
min, and cell lysates were prepared for cAMP measurement using the cAMP Direct EIA 
Kit (Assay Designs) according to the manufacturer’s instructions. 
 
Statistical analysis 
Statistical significance was analyzed using the Prism 5.01 statistical program (GraphPad 
Software, San Diego, CA).  The Kaplan Meier and log-rank methods were used to 
analyze survival rates.  Comparisons between two experimental groups were performed 
using the Student’s t test.  Comparisons among three or more experimental groups were 
performed with ANOVA and a post hoc Bonferroni test.  A value of p<0.05 was 






CHAPTER 3: Comparison of Conditioning Regimens for AM Reconstitution and 
Innate Immune Function Post-BMT 
 
Introduction 
The lung has the largest interface with the outside environment of any internal 
organ in the body.  As such, the lung is constantly bombarded with foreign particles and 
pathogens.  Active host defense requires the orchestration of innate immune cells and 
immune mediators such as cytokines, chemokines and eicosanoids to aid in the 
recognition, containment and clearance of microorganisms (167).  Unfortunately, patients 
who have undergone HSCT are at risk for pulmonary infections (7, 8, 168, 169) and 
pneumonia remains the leading infectious cause of death despite the implementation of 
numerous prophylactic strategies and advances in diagnosis and treatment (170).  These 
transplant patients manifest increased susceptibility to infections for periods of time 
(months to years) post-transplantation extending long after engraftment of leukocytes 
from donor sources (8, 171). 
We previously developed a murine model of syngeneic BMT and have 
demonstrated that these mice are more susceptible to P. aeruginosa pneumonia due to 
defects in pulmonary innate immune function.  We found that by week 3 post-BMT, AMs 
from these mice are >87% donor-derived (168) but are defective in their ability to both 




Interestingly, we found that this defect in host defense post-BMT is related to elevated 
AM production of PGE2, a known inhibitor of host defense (163, 168, 172).   However, 
one caveat to the extrapolation of these findings is that the experimental conditioning 
regimen utilized in our previous studies does not mimic human clinical practice.  The 
conditioning regimen employed in these studies involved 13 Gy of TBI followed by 
reconstitution with 5 x 10
6
 whole bone marrow cells + 1 x 10
6
 syngeneic splenic T cells 
(TBI + T).  Thus, to determine the applicability of our findings to more clinically relevant 
conditioning regimens, we compared the level of AM reconstitution and PG production 
following multiple TBI and chemotherapy preparative regimens.  Overall, our results 
demonstrate that significant reconstitution of AMs from donor bone marrow following 
either TBI or dual busulfan/cyclophosphamide chemotherapy conditioning results in 






Optimal repopulation of AMs occurs at week 5 post-BMT using 13 Gy TBI 
 We first wanted to characterize a model for transplantation following irradiation 
conditioning that would result in significant reconstitution of AMs from donor bone 
marrow without the inoculation of splenic T cells.  In order to determine the optimal 
timing and dose of TBI for AM reconstitution post-BMT, we transplanted CD45.2 mice 
with 5 x 10
6
 whole bone marrow cells from CD45.1 mice following conditioning with 
6.5, 8, 13 or 17 Gy TBI. The 17 Gy dose of TBI was lethal to over 60% of mice despite 
bone marrow transfer and surviving mice were not used for analysis.  However, all mice 
survived conditioning with 6.5, 8 and 13 Gy TBI. There was a dose-dependent increase in 
the percentage of donor-derived AMs and peripheral (spleen) cells, with the highest 
repopulation seen at 13 Gy (Table 3.1).  Figure 3.1 shows representative flow cytometry 
characterization of the donor vs. host reconstitution seen in the BAL of mice 5 weeks 
following 8 and 13 Gy TBI.  Ultimately, week 5 following 13 Gy TBI was chosen as the 
optimal TBI regimen for further study. 






Figure 3.1: Donor vs. host reconstitution of BAL post-TBI conditioning 
Mice were conditioned with either 8 Gy or 13 Gy of TBI (delivered in a split dose 
separated by 3 h) and were transplanted with 5 x 10
6
 bone marrow cells.  BAL was 
performed 5 weeks post-transplant, and cells were analyzed for expression of CD45.1 
(PE-FL2) vs. CD45.2 (FITC-FL1) to differentiate donor vs. host reconstitution.  A and B, 
Dot plot and histogram for CD45.1 PE stain showing unstained cells post-13Gy TBI.  
Background staining is approximately 7% with this gating strategy; C and D, Dot plot 
and histogram for CD45.1 stain of BAL from mice post-8 Gy TBI. In this example, 48% 
of the cells are donor-derived; E and F, Dot plot and histogram for CD45.1 stain of BAL 






TBI conditioning is more effective in reconstitution of AMs from donor bone marrow 
 We next wanted to compare the effectiveness of chemotherapy conditioning 
regimens to irradiation conditioning regimens.  CD45.1 mice were used as bone marrow 
donors for CD45.2 recipients following the conditioning regimens noted in Table 3.2.  5 
weeks post-BMT, AMs were harvested, and the frequency of donor cell reconstitution 
was determined by calculating the percentage of AMs expressing either the CD45.1 or 
CD45.2 allele using flow cytometry. At this time point, we found that significant AM and 
splenocyte donor reconstitution was only observed following TBI, TBI + T, or dual 
chemotherapy conditioning (Table 3.2).  Ultimately, TBI conditioning was more efficient 
than dual chemotherapy conditioning in the reconstitution of AMs from donor bone 
marrow. Additionally, we characterized the total cellularity of BAL from 13 Gy TBI and 
dual chemo mice 5 weeks post-BMT.  By morphological assessment, we found that 











Figure 3.2: Differential analysis of BAL cells post-BMT 
BAL cells were collected from TBI or dual chemo BMT mice at week 5 post-transplant.  
BAL cells were cytospun and stained with modified Wright-Geimsa stain.  Greater than 
85% of the cells collected from the lung lavage had the characteristic morphology of 
AMs at this time point.  
 
Significant reconstitution of AMs from donor bone marrow is associated with elevated 
production of PGE2 
 We previously demonstrated that AMs from TBI + T BMT mice display elevated 
PGE2 production relative to non-transplant control AMs (68).  Therefore, we wanted to 
determine whether this increase in AM PGE2 production from irradiated BMT mice also 
characterizes AMs from chemotherapy conditioned BMT mice. We found that the 
conditioning regimens associated with significant turnover of AMs from donor bone 




PGE2 production 5 weeks post-BMT, as compared to AMs from control mice (Fig 3.3, 
panel A). To determine whether this elevation was specific to PGE2, we measured the 
levels of a stable metabolite of PGI2 (6-keto PGF1α) in supernatants of AMs from control, 
TBI BMT, and dual chemo BMT mice.  The levels of 6-keto PGF1α were elevated in 
mice transplanted by both regimens; however these levels only reached statistical 
significance in the cells from the TBI mice (Figure 3.3, panel B).  Thus, it is likely that 
following BMT there is a general upregulation of PGs in the lung. 
 
Figure 3.3: Prostaglandin secretion by AMs post-BMT 
AMs were harvested from control, TBI + T, TBI, dual chemo, cyclo, bus lo, or bus hi 
conditioned BMT mice.  Cells were cultured at 5 x 10
5
/ml for 24 h, and PGE2 (panel A) 
and 6-keto PGF1α (panel B) were measured in overnight culture supernatants by EIA 






Impaired AM phagocytosis characterizes both TBI BMT and dual chemo BMT mice 
We next wanted to determine whether AM phagocytosis would be similarly 
impaired following either a TBI BMT or dual chemo BMT protocol.  AMs were 
harvested from control, TBI BMT, and dual chemo BMT mice at week 5 post-BMT, and 
AM phagocytosis of non-opsonized bacteria was assessed in the presence or absence 
indomethacin.  AMs from both TBI BMT and dual chemo BMT mice were similarly 
defective in their ability to phagocytose bacteria (Figure 3.4, panel A).  Furthermore, 
inhibition of PG synthesis by the AMs improved phagocytosis to control levels in both 
groups of BMT mice (Figure 3.4, panel A).   Thus, overproduction of PGE2 (and possibly 
PGI2) likely contributes to impaired AM phagocytosis observed in these mice, regardless 
of the conditioning regimen employed. 
 
Both TBI and dual chemo BMT mice display impaired pulmonary host defense  
To determine whether host defense was impaired following either conditioning 
regimen, control, TBI BMT, and dual chemo BMT mice were i.t. injected with a 
sublethal dose P. aeruginosa, and bacterial burden was assessed in lung samples 24 h 
later.  Whereas control mice showed evidence of bacterial clearance, both the TBI BMT 
and dual chemo BMT mice were similarly deficient in their ability to clear the bacterial 
challenge (Figure 3.4, panel B).  These results mirror our previous findings using the TBI 





Figure 3.4 AM function and host-defense post-BMT 
A, AMs were harvested from control, TBI BMT, or dual chemo BMT mice, and AM 
phagocytosis was assessed as described in Materials and Methods, n=6.  B, Control, TBI 
BMT, and dual chemo BMT mice were given a sublethal dose of P. aeruginosa by i.t. 
injection 5 weeks post-BMT.  Lungs were harvested 24 h later, and bacterial burden was 









 Pulmonary complications, particularly infections, remain the leading cause of 
morbidity and mortality in patients undergoing HSCT, despite advances in prophylaxis 
(7, 8, 171).  This is likely due to defects observed in pulmonary innate immunity post-
transplant (173).  Our previous work established a murine model of BMT (TBI + T) 
which was characterized by overproduction of PGE2, impaired AM phagocytosis, and 
diminished pulmonary host defense (168, 172).  However, the TBI + T conditioning 
regimen used in our earlier studies does not mimic clinical practice (8, 174-176).  
Additionally, the TBI + T conditioning regimen results in substantial reconstitution of 
AMs at an earlier time point (week 3) (168) than occurs when T cells are not added to the 
donor inoculum (177).    Thus, we wanted to assess the effect of other conditioning 
regimens on AM reconstitution and function. 
TBI conditioning was superior to all tested methods of chemotherapy 
conditioning in the reconstitution of AMs from donor bone marrow.  Only the dual 
chemotherapy regimen (25 mg/kg busulfan x 4 days followed by 100 mg/kg 
cyclophosphamide x 2 days) resulted in significant AM reconstitution from donor bone 
marrow (Table 3.2).  Furthermore, AM reconstitution was only seen in situations where 
there was also extensive peripheral (splenocyte) reconstitution (Table 3.2).   
Previous studies have suggested that approximately 20% of AMs are capable of 
extensive replication and colony formation in vitro, (178).  This population of cells, 
known as AM colony forming cells (AL-CFCs), are moderately resistant to ionizing 
irradiation (179) and likely represents a local lung progenitor cell for AMs.  Using 




CFC population was not ablated, AMs were repopulated by host cells (presumably the 
lung-resident AL-CFC) (180).  However, high dose irradiation schemes (>9Gy) ablated 
the AL-CFC population and resulted in AM repopulation by donor bone marrow cells 
(180).  Our present results agree with these observations and confirm that 8 Gy TBI 
results in approximately 45% AM reconstitution from donor bone marrow, whereas high 
dose irradiation (13 Gy) results in approximately 80% AM repopulation from donor 
marrow (Fig. 3.1).  Furthermore, these data suggest that of the chemotherapy regimens 
tested, only the dual chemotherapy regimen results in AM repopulation from donor bone 
marrow.  We speculate that the 13 Gy TBI and dual chemo regimens likely ablate the 
AL-CFC local lung progenitors.   Alternatively, these results may suggest that AM 
reconstitution from donor bone marrow requires significant lung injury/inflammation 
induced by either TBI or chemotherapy.  A previous report by Maus et al. suggests that 
lung inflammation is required for efficient exchange of AM populations from circulating 
bone marrow-derived progenitors (181).  In support of this idea, the regimens which 
result in significant AM repopulation are also associated with greater cellularity in the 
BAL (Fig. 3.2). 
Like the TBI regimen, the dual chemotherapy protocol was also the only 
chemotherapy-based protocol to result in significant secretion of PGE2 by AMs post-
BMT (Fig. 3.3, panel A).  Similarly, metabolites of PGI2 were also elevated in AMs from 
the TBI regimen (and to a lesser extent in the dual chemo regimen), although the levels of 
this metabolite were expressed at lower levels than PGE2 (Fig. 3.3, panel B).  This 




all PGs.  Given that PGI2 and PGE2 both induce cAMP elevation, the downstream effects 
of either PGE2 or PGI2 signaling on host defense are presumably similar (163, 182). 
Elevated PGE2 synthesis is not restricted to donor-derived AMs post-BMT. We 
previously reported that PGE2 levels are also elevated in AECs, neutrophils (172), and 
within the peritoneal cavity (data not shown) following the TBI + T regimen.  
Furthermore, we found in a preliminary experiment that production of PGE2 is 
significantly elevated in both donor- and host-derived AMs compared to AMs from 
control mice; however, PGE2 production by donor-derived AMs is significantly higher 
than host-derived AMs (data not shown).  Thus, BMT likely results in global increases in 
PG production from cells of both donor and host origin.  While it is not clear exactly 
what the trigger for elevated PG production is post-BMT, we speculate that oxidative 
stress or reactive oxygen species, a known inducer of PGE2 (183), may play a role 
following the TBI and dual chemotherapy regimens. 
We next wanted to determine whether the elevated levels of PGE2 following BMT 
with either the TBI or the dual chemotherapy regimen would result in similar alterations 
in AM phagocytosis and host defense.  We chose the TBI and dual chemotherapy 
regimens for analysis, because these conditioning regimens mimic human transplantation 
protocols and provide optimal donor cell reconstitution (174-176).  5 weeks post-BMT, 
AMs from BMT mice conditioned with either regimen were similarly defective in 
phagocytosis when compared to control AMs, and this inhibition could be reversed by the 
addition of indomethacin (Fig. 3.4, panel A).  Impaired AM function in both the TBI and 
dual chemotherapy regimens likely led to similar defects in pulmonary clearance 




myeloablative conditioning regimens (whether TBI or chemotherapy based) result in 
significant turnover of AMs from donor bone marrow and are associated with elevated 
AM production of PGs, impaired AM function, and diminished host defense.  
Interestingly, elevated levels of PGE2 have been noted in the plasma of patients 
undergoing autologous BMT (184).  The conditioning regimens differed between the 
patients (TBI/chemotherapy v. chemotherapy alone), but PGE2 levels were elevated in all 
cases (184).  Thus, our results may be widely applicable to HSCT in patients.   
 We were pleased to discover that our dual chemotherapy model of conditioning 
closely mimicked the hallmark features of our experimental TBI model.  Both models 
show increases in AM PGE2 production and similar defects in AM host defense.  Our 
next goal will be to uncover the downstream signaling events which mediate the PGE2-
induced immunosuppression post-BMT.  For these studies, we plan to focus on the TBI 
model of conditioning, given that this regimen provides the greatest level of donor-cell 
reconstitution in the lung.  This will be an important feature for our model in future 








HSCT is an effective treatment for certain forms of cancer and genetic diseases.   
However, delays in immune reconstitution render HSCT patients susceptible to infection 
(7, 31).  Even after immune reconstitution, donor-derived cells are often functionally 
immature, and patients remain at risk for infectious complications months to years post-
transplant.  This susceptibility is noted in both allogeneic and autologous transplant 
recipients (8, 10). 
Bacterial pneumonia is a common infectious complication post-HSCT and 
remains one of the leading causes of infection-related patient mortality (31, 185).  This 
incidence is likely related to impaired pulmonary innate immunity.  AMs comprise up to 
95% of the immune cells in the alveolar space and are essential in mediating innate 
immune responses in the lung (3-5).  Post-allogeneic HSCT, AMs have a decreased 
ability to phagocytose and kill bacteria (104).  Furthermore, neutrophils recruited to sites 
of infection display impaired chemotaxis and killing ability (105).   Allogeneic 
transplants, however, have multiple confounding factors, such as immunosuppressive 
drug therapy and graft-versus-host disease, which can impair immune function (7, 8).  




factors, are useful for investigating the effect of conditioning and reconstitution alone on 
pulmonary host defense. 
We previously developed a mouse model of syngeneic bone marrow transplant 
(BMT) to determine how HSCT alone impacts host defense in the lung.  Compared to 
non-transplant controls, BMT mice are more susceptible to pneumonia following i.t. 
challenge with P. aeruginosa (106).  Furthermore, BMT AMs display impaired host 
defense mechanisms in ex vivo assays, including decreased phagocytosis, bacterial 
killing, and TNF-α production.  Impaired bacterial killing is also observed in recruited 
lung neutrophils (68).  These defects in host defense were directly related to 
overproduction of prostaglandin E2 (PGE2) in the lung post-BMT (68, 185, 186).  PGE2 is 
a lipid mediator with a variety of immunosuppressive properties.  Several studies have 
shown that PGE2 inhibits bacterial killing, phagocytosis (124, 163), chemotaxis (187), 
and production of proinflammatory mediators in leukocytes (188-190).  However, a 
mechanism for this is not well described, and it remains unclear how overproduction of 
PGE2 post-BMT impairs pulmonary host defense. 
In this study, we suggest a role for IRAK-M as a mediator of PGE2-induced 
immunosuppression post-BMT.  IRAK-M is a member of the IRAK family of 
serine/threonine kinases involved in MyD88-dependent IL-1R/TLR signaling.  In mice, 
IRAK-M is expressed mainly in monocytic cells in response to repeated endotoxin 
exposure (61, 133, 134).  To prevent excessive inflammatory responses to endotoxin, 
IRAK-M limits proinflammatory cytokine production by inhibiting MyD88-dependent 
IL-1R/TLR signaling (61, 134).  This inhibitory response may also be induced during 




proinflammatory cytokine production (144, 191).  Given the role for IRAK-M in 
immunosuppression, we hypothesize that overproduction of PGE2 post-BMT upregulates 
IRAK-M expression in AMs, thus inhibiting host defense.    
To address this hypothesis, expression of IRAK-M was measured in BMT and 
non-transplant control AMs.  In addition, experiments were setup using IRAK-M 
deficient mice to determine the role of IRAK-M in pulmonary host defense post-BMT.  
We show for the first time that PGE2 signaling can upregulate IRAK-M expression in 






BMT AMs have elevated IRAK-M expression 
IRAK-M can limit proinflammatory cytokine production in macrophages (61, 
134).  Given that AMs have impaired TNF-α production post-BMT (106), we wanted to 
determine whether IRAK-M expression was elevated in BMT AMs.  AMs from BMT 
and non-transplant control mice were harvested and analyzed for IRAK-M mRNA and 
protein expression.  Relative to control AMs, BMT AMs had approximately a 3.5-fold 
increase in both IRAK-M mRNA (Fig. 4.1, panel A) and protein (Figs. 4.1, panels B and 
C) expression.   IRAK-M protein expression was also measured in neutrophils recruited 
to the lungs of control and BMT mice following LPS i.t. injection.  No appreciable 
differences were observed in IRAK-M protein expression between control and BMT 







Figure 4.1: IRAK-M mRNA and protein is elevated in BMT AMs. 
Mice were given a syngeneic BMT and harvested 5-6 weeks post-BMT.  AMs and 
recruited lung neutrophils were harvested by BAL as described in Materials and Methods 
from BMT and control mice.  A, mRNA was prepared and analyzed by semiquantitative 
real-time RT-PCR for expression of IRAK-M in AMs.  For each sample, expression of 
IRAK-M was normalized to β-actin.  The average of the normalized control samples was 
set to 1, and relative IRAK-M expression in BMT samples was measured by the ΔΔCT 
method (n=3 combined from 2 experiments).  B, Protein lysates of control and BMT 
AMs were prepared, and expression of both IRAK-M and β-actin was measured by 
Western blot analysis.  Blot shown contains samples from independent experiments.  C, 
Protein expression was quantified by densitometry.  For each sample, expression of 
IRAK-M was normalized to β-actin.  A single control sample was then set to 1 and all 
other samples were graphed relative to that control value (**, p< 0.01; n=4).  D, IRAK-M 
protein expression was measured by Western blot analysis in control and BMT lung 
neutrophils recruited via i.t. LPS injection as described in the Materials and Methods 
(n=2). 
 
Elevated IRAK-M expression in BMT AMs is related to overproduction of PGE2 
Our previous work has demonstrated that  BMT AMs display increased PGE2 
production relative to control AMs (68), and this elevation in PGE2 production is 




of LT synthetic enzymes in BMT AMs (Fig. 4.2).  To determine whether elevated IRAK-
M expression in AMs is related to increased PGE2 signaling, WT non-transplant AMs 
were cultured overnight with or without 10 nM PGE2.  PGE2 treatment increased IRAK-
M protein expression 2.5-fold over untreated AMs (Figs. 4.3, panels A and B).  Similar 
results were observed by treating AMs with 10 nM butaprost free acid (data not shown), 
an agonist selective for the E prostanoid 2 (EP2) receptor which is known to mediate the 
suppressive effect of PGE2 on AM phagocytosis and killing (68, 123, 163).   
We next sought to determine whether overproduction of PGE2 was elevating 
IRAK-M expression in BMT AMs.  AMs from BMT and control mice were cultured 
overnight in the presence or absence of 5 µM indomethacin (or vehicle control) to inhibit 
endogenous PGE2 production.  Relative to untreated control AMs, vehicle-treated BMT 
AMs expressed 3.1-fold more IRAK-M protein; however, treatment with indomethacin 
reduced elevation of IRAK-M protein in BMT AMs by 40% (Figs. 4.3, panels C and D).  
Inhibition of endogenous PGE2 production was verified by EIA using overnight culture 
supernatants (data not shown).   We then wanted to determine whether in vivo inhibition 
of endogenous PGE2 production could also reduce elevation of IRAK-M in AMs post-
BMT.  24 hours following i.p. injection of either indomethacin or vehicle control into 
BMT mice, we found that AMs from vehicle-treated BMT mice had a 3.2-fold increase in 
IRAK-M expression relative to AMs from untreated control mice (Figs. 4.3, panels E and 
F).  In vivo administration of indomethacin reduced IRAK-M elevation in BMT AMs by 
51%, relative to BMT AMs from vehicle-treated mice (Figs. 4.3, panels E and F).  We 
previously demonstrated that in vivo treatment with indomethacin improved host defense 




that AM overproduction of PGE2 may contribute to elevated IRAK-M expression in AMs 
and decreased host-defense post-BMT. 
 
Figure 4.2: Elevated BMT AM expression of PGE2 synthetic enzymes 
AMs were harvested by BAL as described in Materials and Methods from BMT and 
control mice.  Protein lysates of control and BMT AMs were prepared, and expression of 
cPLA2, COX-2, 5-LO, FLAP, PGES1, PGES2, and β-actin was measured by Western 
blot analysis.  Blots are representative of an n=3 per group. 
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Figure 4.3: PGE2 increases IRAK-M expression in BMT AMs.   
A, Protein lysates were prepared from WT non-transplant AMs cultured overnight at 5 x 
10
5
 cells/well in the presence or absence of 10 nM PGE2 in CM.  IRAK-M and β-actin 
protein expression was analyzed by Western blot.  Blot shown is from a single 
experiment representative of two. B, Densitometry quantification of blots from two 
experiments as shown in part A.  IRAK-M expression was normalized to β-actin for each 
sample and expression was graphed as fold change above control. C, Protein lysates were 
prepared from control and BMT AMs cultured overnight at 5 x 10
5
 cells/well in the 
presence or absence of 5 μM indomethacin (to inhibit PGE2) or vehicle (0.25 % ethanol) 
in CM.  IRAK-M and β-actin protein expression was analyzed by Western blot.  Blot 
shown is from a single experiment representative of two.  D, Densitometry quantification 
of blots from two experiments as shown in part C.  E, BMT mice were i.p. injected with a 
100 μL dose of either 1.2 mg/kg indomethacin (Sigma) or 1% DMSO (vehicle) in sterile 
PBS.  24 hours following i.p. injection, AMs were harvested from control and BMT 
mice, and protein lysates of AM samples were prepared.  IRAK-M and β-actin protein 
expression was analyzed by Western blot.  Blot shown is from one experiment 
representative of two. F, Densitometry quantification of blots from two experiments as 




IRAK-M -/- BMT mice are protected from pneumonia following P. aeruginosa infection 
Expression of IRAK-M is associated with reduced host defense following in vivo 
bacterial challenge (134, 144).  Since IRAK-M is elevated in BMT AMs (Fig. 4.1), we 
wanted to determine whether the absence of IRAK-M in the hematopoietic cell 
compartment could improve pulmonary host defense post-BMT.  Control, WT BMT (WT 
> WT), and IRAK-M -/- BMT (IRAK-M -/- > WT) chimeric mice were challenged with 
a 24 hour, acute P. aeruginosa lung infection.  As previously published, WT BMT mice 
had increased bacterial burden in the lung (Fig. 4.4, panel A) and blood (Fig. 4.4, panel 
B) relative to control mice.  However, IRAK-M -/- BMT mice, had enhanced clearance 
of P. aeruginosa from the lung and reduced dissemination to the blood relative to WT 
BMT mice.  In fact, the host defense capabilities of IRAK-M-/- BMT mice were not 
significantly different from control mice.  Overall, these results suggest that 
hematopoietic IRAK-M expression post-BMT impairs host defense against P. aeruginosa 





Figure 4.4:  Restored host defense in IRAK-M -/- BMT mice following acute P. 
aeruginosa lung infection 
Bone marrow from WT or IRAK-M -/- mice was transplanted into lethally-irradiated WT 
recipients.  Control, WT BMT (WT > WT), and IRAK-M -/- BMT (IRAK-M -/- > WT) 
mice were i.t. injected with a 50 μL dose of 5 x 10
5
 CFU P. aeruginosa 5-6 weeks post-
BMT.  24 hours following infection, bacterial burden of whole lung (A) and blood (B) 
samples from each mouse was assessed by CFU assay (*, p < 0.05; **, p< 0.01; 
combined data from two independent experiments, n=6-10 mice per group). 
 
IRAK-M -/- BMT mice have a survival advantage following lethal P. aeruginosa infection 
 IRAK-M -/- BMT mice show restored bacterial clearance relative to WT BMT 




enhanced bacterial clearance in IRAK-M -/- BMT mice would provide a survival 
advantage following a lethal P. aeruginosa lung infection, we i.t. injected control, WT 
BMT, and IRAK-M -/- BMT mice with 1.5 x 10
6
 CFU P. aeruginosa.  As predicted, the 
rate of survival of IRAK-M -/- BMT and control mice was not statistically different (p= 
0.274), but WT BMT mice had a significantly increased mortality rate compared to both 
control and IRAK-M -/- BMT mice (p > 0.05; Fig 4.5). 
 
 
Figure 4.5: IRAK-M -/- BMT mice have survival advantage following lethal P. 
aeruginosa infection.   
Control, WT BMT, and IRAK-M -/- BMT mice were i.t. injected with a 50 μL lethal 
dose of 1.5 x 10
6
 CFU P. aeruginosa and rate of mortality was monitored for 2 days.  








Inflammatory response during early P. aeruginosa infection 
 We next wanted to determine whether the improvement in host defense in IRAK-
M-/- BMT mice was a result of differential accumulation of leukocytes in the lung during 
early infection.  Control, WT BMT, and IRAK-M -/- BMT mice were injected with P. 
aeruginosa and 4 h later, lungs were harvested to assess leukocyte populations.  Total 
lung leukocyte number was similar between all three groups (Fig. 4.6, panel A).  The 
percentage of lung macrophages, lymphocytes, neutrophils, and eosinophils was not 
statistically different between WT BMT and IRAK-M -/- BMT mice 4 h post-infection 
(Fig. 4.6, panel B).  Percent neutrophil accumulation ranged between 8-25% among 
control, WT BMT, and IRAK-M -/- BMT mice at 4 h post-infection (Fig. 4.6, panel B), 
but increased to 67-78% 24 hours post-infection (data not shown).  Frequency of lung 
lymphocyte populations was also determined among uninfected mice, and no significant 





Figure 4.6: Inflammatory response during early P. aeruginosa infection 
Control, WT BMT, and IRAK-M -/- BMT mice were i.t. injected with a 50 μL dose of 5 
x 10
5
 CFU P. aeruginosa.  4 hours following infection, whole lung samples were 
harvested from mice, and lung leukocytes were isolated, counted, and stained for 
differential cell analysis as described in the Materials and Methods. A, Percentage of 
macrophages (MΦ), lymphocytes, neutrophils, and eosinophils, and B, total lung 





Figure 4.7: Lung lymphocyte populations in control and BMT mice 
Lungs were harvested from uninfected control, WT BMT, and IRAK-M -/- BMT mice 5-
6 weeks post-BMT.  Lung leukocytes were isolated and analyzed by flow cytometry for 
specific cell surface markers as described in Materials and Methods to determine the total 
number of CD4 T cells (A), CD8 T cells (B), NK-T cells (C), B cells (D), and NK cells 








IRAK-M -/- BMT AMs display enhanced phagocytosis and killing of P. aeruginosa 
Restored pulmonary host defense in IRAK-M -/- BMT mice may be explained by 
enhanced AM function in the absence of IRAK-M.  To verify this hypothesis, ex vivo 
phagocytosis of FITC-P. aeruginosa was compared among AMs harvested from control, 
WT BMT, and IRAK-M -/- BMT mice.  Similar to previous reports, WT BMT AMs 
displayed a 35% decrease in phagocytosis relative to control AMs; however, IRAK-M -/- 
BMT AMs had restored phagocytic ability (Fig. 4.8, panel A).  Bacterial killing was also 
assessed in control and BMT AMs ex vivo.  Relative to WT BMT AMs, survival of 
ingested bacteria was significantly diminished in the IRAK-M -/- BMT AMs (Fig. 4.8, 
panel B).  The amount of surviving bacteria ingested by IRAK-M -/- BMT AMs was not 
statistically different from control AMs, indicating restoration of bacterial killing by 





Figure 4.8: Restored phagocytosis and killing in IRAK-M -/- BMT AMs 
AMs were harvested from control, WT BMT, and IRAK-M -/- BMT mice and cultured at 
2 x 10
5
 cells/well overnight. A, Phagocytosis of unopsonized FITC-P. aeruginosa and B, 
killing of P. aeruginosa was measured as described in Materials and Methods.  Note 
impaired AM killing correlates with increased percentage of surviving bacteria relative to 









IRAK-M -/- BMT AMs have restored TNF-α and cys-LT production 
Macrophage production of cys-LTs enhances phagocytosis, microbial killing, and 
production of proinflammatory cytokines such as TNF-α (70, 72, 165, 192).  We have 
previously demonstrated that AMs from BMT mice are defective in production of both of 
these mediators (68, 106).   We therefore wanted to determine whether improved host 
defense mechanisms in IRAK-M -/- BMT AMs were also marked by restored AM cys-
LT and TNF-α production.  AMs harvested from control, WT BMT, and IRAK-M -/- 
BMT mice were cultured unstimulated overnight and supernatants were analyzed for cys-
LT and TNF-α production.  WT BMT AMs had significantly reduced levels of TNF-α 
(Fig. 4.9, panel A) and cys-LTs (Fig. 4.9, panel B) relative to control AMs.  In contrast, 
levels of both TNF-α and cys-LTs were restored in IRAK-M -/- BMT AMs to levels seen 
in control AMs.  Interestingly, this same trend was observed in whole lung homogenates 
from control, WT BMT, and IRAK-M -/- BMT mice given P. aeruginosa at 4 hours post-
infection.  TNF-α and cys-LT production was significantly reduced in WT BMT lung 
samples relative to control; however, IRAK-M -/- BMT mice had restored production of 





Figure 4.9: IRAK-M -/- BMT mice have restored TNF-α and cys-LT production 
AM TNF-α (A) and cys-LT (B) production was measured by EIA/ELISA as described in 
Materials and Methods using overnight culture supernatants in complete media and 
serum-free media respectively from unstimulated AMs plated at 2 x 10
6 
cells/mL (**, p< 
0.01; n=4-7 per group).  TNF-α (C) and cys-LT (D) levels in lung homogenates 4 hours 
post-i.t. infection with 50 μL dose of 5 x 10
5
 CFU P. aeruginosa (*, p<0.05; ***, p< 










Altered BMT AM TLR, MARCO, and TREM-1 expression 
 Enhanced macrophage production of proinflammatory cytokines and 
phagocytosis can be related to altered/elevated expression of cell surface receptors such 
as TLRs or scavenger receptors (193, 194).  We wondered whether such alterations could 
explain the differences we observe between WT BMT and IRAK-M -/- BMT AMs in 
their host defense function.  Expression of mRNA for TLR-2, -4, and -9, was measured 
(Fig. 4.10, panels A-C).  The mRNA expression for TLR2 was downregulated in both 
BMT AM groups relative to control AMs.  TLR4 mRNA expression was similar between 
control, WT BMT, and IRAK-M -/- BMT AMs.  TLR9 mRNA expression was 
upregulated approximately 1.7-fold and 1.9-fold in WT BMT and IRAK-M -/- BMT 
AMs respectively.  Additionally, we measured mRNA expression of the scavenger 
macrophage receptor with collagenous structure (MARCO, Fig. 4.10, panel D). 
Interestingly, we found that MARCO mRNA expression was downregulated not only in 
WT BMT AMs relative to control AMs, but MARCO was also downregulated in IRAK-
M -/- BMT AMs.  Finally, we looked at expression of the cell surface molecule, 
triggering receptor expressed on myeloid cells (TREM)-1.  However, TREM-1 mRNA 
expression was reduced nearly 50% in both WT BMT and IRAK-M -/- BMT AMs 





Figure 4.10: BMT AM TLR, MARCO, and TREM-1 expression 
mRNA from AMs was prepared and analyzed by semiquantitative real-time PCR for 
expression of TLR2 (A), TLR4 (B), TLR9 (C), MARCO (D), and TREM-1 (E).  For each 
sample, mRNA expression of the gene of interest was normalized to β-actin.  The average 
of a single control sample was set to 1, and relative mRNA expression in other samples 
was measured by the ΔΔCT method (*, p < 0.05; samples were generated in two 








Both WT and IRAK-M -/- BMT AMs have elevated PGE2 production and EP2 receptor 
expression 
Post-BMT, elevated PGE2 production in the lung significantly impairs AM 
phagocytosis and killing (68, 185, 186), and this is associated with elevated EP2 receptor 
expression in BMT AMs (68, 159).  Therefore, we wanted to determine whether 
improved pulmonary host defense in IRAK-M -/- BMT mice was a result of reduced 
PGE2 production and/or altered EP2 receptor expression in AMs.  AMs were harvested 
from control, WT BMT, and IRAK-M-/- BMT mice, and AM EP2 mRNA expression 
was measured by real-time RT-PCR.  It should be noted that reliable Abs to detect EP2 in 
the mouse are not available.  Expression of EP2 in AMs was elevated in both transplant 
groups relative to control (Fig. 4.11, panel A).  As noted previously (68), analysis of 
overnight culture supernatants revealed an 8-fold increase in WT BMT AM PGE2 
production over control AMs (Fig. 4.11, panel B).  Interestingly, we found that IRAK-M 
-/- BMT AMs overproduced PGE2 by 32-fold relative to control AMs.  This phenotype of 
PGE2 overproduction was unique to the transplant environment, given that PGE2 
production by AMs isolated from IRAK-M -/- non-transplant mice was comparable to 
WT control AMs (data not shown).  Thus, AMs from IRAK-M -/- BMT mice display 





Figure 4.11: WT BMT and IRAK-M -/- BMT AMs display increased PGE2 
production and EP2 receptor expression 
A, mRNA from AMs was prepared and analyzed by semiquantitative real-time PCR for 
expression of EP2.  For each sample, EP2 expression was normalized to β-actin.  The 
average of a single control sample was set to 1, and relative EP2 expression in other 
samples was measured by the ΔΔCT method (*, p < 0.05; samples were generated in two 
independent experiments, n=3-4 per group).  B, AMs were harvested and cultured 
overnight at 2 x 10
6
 cells/mL. The following day, supernatants were collected and 
analyzed for PGE2 concentration by EIA as described in Materials and Methods (** p < 








IRAK-M is necessary for PGE2-mediated inhibition of AM phagocytosis 
 IRAK-M -/- BMT AMs have restored host defense (Figs. 4.8 and 4.9), despite 
overproduction of PGE2 and elevated EP2 receptor expression (Fig. 4.11).  Therefore, we 
wanted to determine whether IRAK-M was required for PGE2 to mediate inhibition of 
AM host defense.  Ex vivo phagocytosis of FITC-labeled bacteria was assessed in non-
transplant WT and IRAK-M -/- AMs pretreated in the presence or absence of 10 nM 
PGE2 .  PGE2 significantly inhibited WT AM phagocytosis but did not inhibit IRAK-M -
/- AM phagocytosis (Fig. 4.12).  Thus, in the absence of IRAK-M, AMs were not 
sensitive to the inhibitory effects of PGE2. 
 
Figure 4.12: IRAK-M mediates PGE2 inhibition of AM phagocytosis.   
AMs were harvested from non-transplanted WT and IRAK-M -/- mice and cultured at 2 x 
10
5
 cells/well overnight. Phagocytosis of unopsonized FITC-E. coli was measured 
following 15 minute pretreatment with 10 nM PGE2 as described in Materials and 





Overproduction of PGE2 in the lung post-BMT significantly diminishes AM 
phagocytosis, killing, and TNF-α production (68, 159, 185, 186).  Although a mechanism 
has not been defined, our current study suggests a role for IRAK-M in PGE2-induced 
immunosuppression post-BMT.  We are the first to show that IRAK-M is elevated in 
BMT AMs, and this phenotype is related to increased PGE2 signaling.  Furthermore, we 
demonstrate a suppressive role for IRAK-M in host defense post-BMT, as genetic 
ablation of IRAK-M in the bone marrow restores AM function and host defense against 
P. aeruginosa lung infection. 
Our results demonstrate that IRAK-M expression is elevated in AMs but not 
elicited lung neutrophils post-BMT (Fig.4.1).  IRAK-M expression has been associated 
mainly with monocytic cells; however, expression has also been detected in tissues as 
well as fibroblasts, B cells, and alveolar epithelial cells (61, 133, 134, 136).  IRAK-M 
expression is rapidly induced by MyD88-dependent IL-1R/TLR signaling as part of a 
negative feedback mechanism.  As a result, IRAK-M stably binds the MyD88 adaptor 
complex and prevents activation of pathways that initiate NFκ-B-induced 
proinflammatory cytokine production (61, 134).  This negative regulation of MyD88-
dependent IL-1R/TLR signaling induces endotoxin tolerance as well as macrophage 
deactivation in sepsis and cancer (144, 191, 195).  In our studies, we show that post-
BMT, elevated IRAK-M expression in AMs is related to increased PGE2 signaling (Fig. 
4.3).  It is interesting to speculate that this may also be a mechanism involved in 
macrophage deactivation in cancer, as certain tumors are known to overproduce PGE2 




PGE2 is a part of the eicosanoid family of lipid mediators with potent 
immunomodulatory functions (72).  PGE2 in particular has a number of 
immunosuppressive properties.  By elevating intracellular cAMP, PGE2 signaling 
activates two key effectors: protein kinase A and Epac-1 (124, 163).  In undefined 
pathways, activation of these two molecules collectively induces production of IL-10 and 
inhibits NFκ-B induced proinflammatory cytokine production, Fc receptor-mediated 
phagocytosis, and microbial killing pathways.  Our results suggest that upregulation of 
IRAK-M may be one mechanistic pathway by which PGE2 signaling limits AM host 
defense.  PGE2 can increase the transcription of IRAK-M within 3 hours of stimulation 
(unpublished observation), and protein levels are elevated by 24 hours post-treatment 
(Fig. 4.3).  However, our results cannot determine whether IRAK-M has direct inhibitory 
effects on phagocytosis and killing, or whether the improved anti-bacterial host defense 
seen in the absence of IRAK-M post-BMT is secondary to the restoration of 
proinflammatory cytokine and/or eicosanoid production.  
Although exogenous and endogenous PGE2 can elevate IRAK-M protein 
expression in AMs as much 3.5-fold above controls (Fig. 4.3), it is possible that factors 
aside from PGE2 may also contribute to elevation of IRAK-M in AMs post-BMT.  We 
previously reported that BMT AMs overproduce GM-CSF relative to control AMs (159).  
Recent studies have shown that GM-CSF regulates expression of IRAK-M in addition to 
other components of the TLR4 signaling pathway in primary mouse AMs (197).  
However, we did not detect increases in IRAK-M protein expression in non-transplant 
AMs following overnight treatment with 50 ng/mL GM-CSF (data not shown); whereas 




treatment.  In addition, it is possible that IRAK-M is upregulated due to increased 
endogenous endotoxin levels following BMT.  Epithelial cell damage caused by TBI 
and/or chemotherapy conditioning regimens can result in loss of gut integrity (198).  This 
can increase gut bacterial leakage and raise levels of circulating endotoxin.  However, 
IRAK-M levels in BMT AMs remain elevated to a similar degree if the AMs are cultured 
overnight in CM or if they are assayed directly from mice.  This suggests to us that the 
elevation in IRAK-M is related to autocrine production of PGE2 in those cultures, rather 
than gut-derived LPS which would presumably have been washed out of the culture.   
We next assessed whether the alteration in AM function between the WT BMT 
and IRAK-M-/- BMT mice could be related to increased TLR and/or scavenger receptor 
expression post-BMT (Fig. 4.10)  We found that expression of TLR2 was increased and 
TLR9 was decreased in AMs from both WT BMT and IRAK-M-/-BMT mice relative to 
control.  Additionally, expression of TLR4 was not different among the three groups.  
MARCO is the major receptor on AMs for binding of non-opsonized particles (199) and 
MARCO-deficient mice are more susceptible to pneumococcal infection (200).  
Expression of the scavenger receptor MARCO, was downregulated in both BMT groups 
relative to control AMs.  The same trend was observed in regard to BMT AM mRNA 
expression of TREM-1, which has been shown to improve bacterial clearance from the 
lung following Streptococcus pneumoniae lung infection via negative regulation of 
IRAK-M (136). Thus, while there are some reductions in these surface molecules 
between the control and BMT groups, the differences we observe in WT BMT and 
IRAK-M -/- BMT AM host defense functions are likely not related to altered expression 




Our data demonstrate that IRAK-M -/- BMT mice display enhanced clearance of 
P. aeruginosa from the lung and diminished dissemination of P. aeruginosa to the blood 
(Fig. 4.4).  Furthermore, IRAK-M -/- BMT mice have a significantly reduced mortality 
rate relative to WT BMT mice following lethal P. aeruginosa lung infection (Fig. 4.5). 
These data suggest that hematopoietic expression of IRAK-M increases susceptibility to 
P. aeruginosa lung infection post-BMT, and ablation of hematopoietic IRAK-M 
expression provides more effective clearance of P. aeruginosa to improve survival rates 
in BMT mice following infection.  Other studies have also demonstrated a protective role 
for IRAK-M deficiency in improved host defense.  In both septic patients and mice, 
IRAK-M expression is elevated in monocytic cells and is associated with increased 
susceptibility to secondary infections, particularly bacterial pneumonia (144, 191).  
Interestingly, impaired pulmonary host defense following sepsis is improved in IRAK-M 
-/- mice (144).  In addition, IRAK-M -/- mice display enhanced ability to clear infection, 
following challenge with S. typhimurium.  This was associated with enhanced 
macrophage TLR signaling and pro-inflammatory cytokine production in response to 
TLR ligand and pathogen stimulus respectively (134).  Therefore, targeting IRAK-M 
may serve a number of therapeutic roles in reducing bacterial infections in 
immunosuppressed patients. 
We also found that the absence of IRAK-M in BMT AMs enhances phagocytosis 
and killing of non-opsonized P. aeruginosa (Fig. 4.8).  Whether TLR signaling regulates 
phagocytosis is unclear.  It has been argued that phagocytosis is a mechanical process 
independent of the TLR signals produced from endocytosed cargo (201-203).  However, 




increases in phagosome maturation or upregulation of gene transcription programs 
associated with phagocytosis (204-206).  Interestingly, cys-LTs are known to enhance a 
number of host defense mechanisms in AMs, such as phagocytosis, killing, and 
proinflammatory cytokine production (70, 72, 165, 192).  Therefore, restored cys-LT 
production in IRAK-M -/- BMT AMs (Fig. 4.9) likely contributes to enhanced 
phagocytosis, killing, and TNF-α production post-BMT.  It is important to note, however, 
that AMs from non-transplanted IRAK-M -/- mice display similar phagocytic ability as 
WT non-transplant mice (Fig. 4.12), and TNF-α production is comparable between 
groups (data not shown).  Thus, these differences may not be apparent under basal 
conditions where expression of IRAK-M is low. 
Given that IRAK-M has been identified in other cell types, we questioned 
whether IRAK-M could also be detected in neutrophils and if so, whether expression of 
IRAK-M in these cells was altered in the setting of BMT.  After eliciting neutrophils to 
the lungs of control or BMT mice via i.t. injection of LPS as described (68, 106), we 
found no difference in total numbers of recruited neutrophils (data not shown).  In these 
recruited lung neutrophils, we could detect IRAK-M by Western blot, but there was no 
increase in BMT neutrophil IRAK-M expression relative to control neutrophils (Fig. 4.1).  
This may reflect the fact that IRAK-M is maximally elevated in these cells in response to 
the LPS recruitment signal.  However, there was no clear evidence that neutrophils 
upregulated IRAK-M in response to BMT.  This is consistent with our earlier findings 
which demonstrated no defect in the ability of neutrophils from BMT mice to 
phagocytose bacteria, despite elevations in neutrophil PGE2 production post-BMT (68, 




recruitment to the lung in response to P. aeruginosa challenge between WT BMT and 
IRAK-M-/- BMT mice.    Both WT BMT and IRAK-M-/- BMT mice were effectively 
able to recruit neutrophils in response to bacterial challenge and no differences were 
noted between the groups (Fig. 4.6).  Taken together, our results suggest that the 
suppressive actions of IRAK-M post-BMT may be restricted to alveolar macrophages.  
These results are also consistent with a previous report which demonstrated impaired 
host-defense against P. aerugionsa following clodronate liposome depletion of AMs 
(207). 
Our earlier studies demonstrated that impaired host defense in AMs post-BMT 
requires elevation in PGE2 production and concomitant increases in expression of the 
inhibitory EP2 receptor.  It is not known for certain why expression of PGE2 is elevated 
post-BMT, but it is likely to be the result of a general upregulation in the transcription or 
stability of all key prostaglandin synthetic enzymes (Figure 4.2). Interestingly, improved 
host defense in IRAK-M -/- BMT mice is observed despite elevated PGE2 production and 
EP2 receptor expression in IRAK-M -/- BMT AMs (Fig. 4.11).  Furthermore, IRAK-M -
/- AMs were insensitive to PGE2-mediated inhibition of non Fc-mediated phagocytosis 
(Fig. 4.12).  This suggests that PGE2 may require IRAK-M to inhibit AM function, and 
therefore, IRAK-M -/- BMT AMs may not be responsive to PGE2-induced 
immunosuppression despite the upregulation of the inhibitory receptor.  PGE2 is also 
known to signal via another inhibitory receptor, EP4 (108).  However, EP4 mRNA 
expression is slightly downregulated in both WT BMT and IRAK-M -/- BMT AMs 
relative to control AMs (data not shown).  We suspect that the high levels of PGE2 




compensation that occurs in the absence of appropriate EP2-induced IRAK-M feedback 
inhibition.  It is likely that TLR-mediated NF-κB activation of COX-2 is unchecked in 
the absence of IRAK-M.  In total, our results demonstrate that IRAK-M is a critical 
mediator of the inhibitory signaling mediated by EP2 activation. 
HSCT patients are at risk for infections with many organisms, and it would be 
interesting to know whether PGE2-induced IRAK-M expression could limit host defense 
against most pathogens.  We speculate that the elevations in IRAK-M will only impair 
innate immune function in AMs, and thus will likely only inhibit host defense against 
pathogens (e.g. bacteria) that are primarily cleared by AMs.  Consistent with this 
hypothesis, treatment of BMT mice with indomethacin did not improve the clearance of 
murine gammaherpesvirus-68, a pathogen known to require CD4 T cell adaptive 
immunity for immune control (208). 
Overall, our data provide further insight into the mechanism by which the 
procedure of transplant (without immunosuppressive therapy or GVHD) can impair 
immune function following complete hematopoietic reconstitution.  While immune 
suppression in humans post-HSCT is likely to be complex, our data suggest that IRAK-M 
likely plays an important role in PGE2-induced immunosuppression post-BMT, and that 
genetic ablation of IRAK-M in bone marrow improves pulmonary host defense post-
BMT.  This presents the possibility for therapeutic targeting of IRAK-M post-BMT to 
improve patient outcomes in response to infection.  An important aspect for our future 
studies will be to find ways to target IRAK-M and to determine the level of suppression 




CHAPTER 5: The Role of PTEN in Impaired Pulmonary Host Defense Post-BMT 
 
Introduction  
AMs are the primary immune cell type in the alveolar space and are critical for 
initiating immune responses against inhaled pathogens (3-5).   However, AMs are 
reported to have decreased host defense capability following HSCT.  Furthermore, 
neutrophils recruited to sites of infection display impaired chemotaxis and killing ability 
post-HSCT (105).   These studies using allogeneic transplant patients, however, involve 
various confounding factors (such as immunosuppressive drug therapy and graft-versus-
host disease) which are known to impair immune function (7, 8).  Thus, the specific 
impact of conditioning and reconstitution alone on pulmonary innate immune function 
remains unclear. 
To determine the impact of HSCT on pulmonary host defense, we previously 
developed a mouse model of syngeneic BMT.  Compared to non-transplant controls, 
BMT mice were more susceptible to P. aeruginosa pneumonia following i.t. infection, 
despite full hematopoietic reconstitution in the lung and periphery (106).  Furthermore, 
donor-derived BMT AMs and recruited lung neutrophils displayed impaired host defense 
functions (68).  We found that this reduction in innate immune function was induced by 
elevated production of the immunosuppressive lipid mediator, PGE2, in the lung post-




PGE2 is known to inhibit bacterial killing, phagocytosis (124, 163), chemotaxis 
(187), and production of proinflammatory mediators in leukocytes (188-190).  At least 
one consequence of increased PGE2 production after transplant is the upregulation of 
IRAK-M which limits AM function (Fig. 4.3).   However, it is not known what 
downstream signaling pathways PGE2 activates to upregulate IRAK-M.   One potential 
candidate in the PGE2 signaling pathway that may regulate IRAK-M is PTEN, which has 
also been reported to negatively regulate phagocytosis and bacterial killing in AMs (120).  
However, it remains unknown whether PTEN regulates AM function in the BMT setting. 
PTEN is a dual-specificity phosphatase that can dephosphorylate both protein and 
lipid targets; however,  PTEN is best characterized by its ability to dephosphorylate the 
lipid second messenger PIP3, a key mediator of the PI3K/AKT signaling pathway (209).  
This dephosphorylation event results in the inhibition of Fcγ-R-mediated phagocytosis of 
IgG-opsonized particles (94, 95).  PTEN phosphatase activity is negatively regulated via 
a number of post-translational mechanisms, including tyrosine phosphorylation (146).  
Interestingly, PGE2 activation of the cAMP signaling cascade has been shown to induce 
PTEN activity via tyrosine dephosphorylation in a SHIP-1 dependent manner (120, 210).  
Furthermore, these studies showed that PGE2-mediated increases in PTEN activity 
diminish AM phagocytosis and killing of IgG-opsonized particles (120).  Additional roles 
for PTEN may also exist in the inhibition of non-Fcγ-R mediated phagocytosis, given that 
PI3K activity has also been reported to contribute to phagocytosis of non-opsonized 
particles (98, 99, 211).  Therefore, we hypothesize that in our model of syngeneic BMT, 
increased PGE2 signaling in the lung inhibits host defense against acute P. aeruginosa 




influence of PTEN in both opsonized and non-opsonized phagocytosis pathways and 
whether PTEN signaling is related to IRAK-M elevation post-BMT. 
To address our hypothesis, we measured PTEN activity and AKT phosphorylation 
levels in BMT and non-transplant control AMs in the presence or absence of an inhibitor 
of endogenous PGE2 production.  Additionally, we transplanted WT mice with bone 
marrow from myeloid-specific PTEN KO mice to determine whether PTEN plays a role 
in impaired pulmonary host defense post-BMT.  We demonstrate that increased PGE2 
signaling augments PTEN activity in BMT AMs and diminishes pAKT levels.  
Furthermore, we show that myeloid-specific ablation of PTEN in the bone marrow of 
transplant mice can restore AM phagocytosis of serum opsonized bacteria and improve 
bacterial clearance following P. aeruginosa infection.  Finally, we demonstrate that the 





Increased PTEN activity and diminished pAKT levels in BMT AMs 
Following syngeneic BMT, AMs display elevated production of PGE2, which 
directly impairs AM phagocytosis and killing of IgG-opsonized and non-opsonized 
particles (68).  Given that PGE2 is known to inhibit FcγR-mediated phagocytosis and 
killing in AMs by upregulating PTEN activity (120), we wanted to determine whether 
overproduction of PGE2 in BMT AMs resulted in elevated PTEN phosphatase activity.  
PTEN was immunoprecipitated from BMT and non-transplant control AMs, and the lipid 
phosphatase activity of the purified PTEN protein was assessed following incubation 
with PIP3.  Relative to control AMs, BMT AMs had approximately a 50% increase in 
PTEN activity (Fig.5.1, panel A).  This increase was blocked in BMT AMs following 
overnight treatment with indomethacin, an inhibitor of endogenous PGE2 production 
(Fig. 5.1, panel A).   
Increased PTEN activity inhibits the activation of a number of downstream targets 
in the FcγR-signaling pathway, such as AKT (146, 209).  To determine whether increased 
PTEN activity in BMT AMs translates into functional AKT suppression, AMs from 
control and BMT mice were stimulated with IgG-opsonized SRBCs to induce 
phosphorylation of AKT.  FcγR stimulation of control AMs induced phosphorylation of 
AKT (Fig. 5.1B, lane 2); however, as previously reported (120), pretreatment with 100 
nM PGE2 blocked FcγR-induced AKT phosphorylation (Fig. 5.1B, lane 3).  As expected, 
BMT AMs had no detectable levels of pAKT following FcγR-stimulation (Fig 5.1B, lane 
5).  pAKT levels were restored in FcγR-stimulated BMT AMs following pretreatment 




PTEN activity and diminished pAKT levels in BMTs AM are related to increased PGE2 




Figure 5.1: Overproduction of PGE2 elevates PTEN activity and diminishes pAKT 
levels in BMT AMs.   
Mice were given a syngeneic BMT and harvested 5-6 weeks post-transplant.  AMs were 
isolated by BAL as described in Materials and Methods from BMT and non-transplanted 
control mice.  A, PTEN protein was immunoprecipitated from whole-cell lysates of AMs 
cultured at 5 x 10
5
 per well in the presence  of 5 μM indomethacin or 0.05% vehicle 
control overnight.  PTEN phosphatase activity was determined as described in Materials 
and Methods.  Results are represented as percent PTEN phosphatase activity relative to 
untreated control group (*, p<0.05; n=3-4 per group combined from 2 experiments).  B, 
AMs were pretreated with either 5 μM indomethacin for 2h or 100 nM PGE2 for 15 mins 
at 37°C.  AMs were then stimulated with IgG-SRBCs (1:10 ratio) for 15 mins at 37°C.  
Following IgG-SRBC stimulation, AMs were prepared for Western blot analysis as 
described in Materials and Methods.  Average relative band densitometry data are 







Inhibition of PTEN activity restores phagocytosis in BMT AMs 
Since PTEN activity is known to inhibit FcγR-mediated phagocytosis in 
macrophages (145), we wanted to determine whether pharmacologic inhibition of PTEN 
activity could restore phagocytosis in BMT AMs.  The phosphatase inhibitor, bpV(pic), 
is known to specifically inhibit PTEN phosphatase activity at concentrations within the 
nanomolar range (6).  We found that pretreating BMT AMs with 100 nM bpV(pic) 
restored phagocytosis of serum opsonized P. aeruginosa to that of control AM levels 
(Fig. 5.2, panel A).  In experiments using non-opsonized P. aeruginosa, bpV(pic) 
treatment was also able to significantly improve the phagocytic function of BMT AMs, 
although not to control AM levels (Fig. 5.2, panel B).  These data suggest that PTEN 
negatively regulates phagocytosis but may play a more important role in the inhibition of 





Figure 5.2: Inhibiting PTEN activity improves BMT AM phagocytic ability. 
AMs were harvested from control and BMT mice and cultured at 2 x 10
5
 cells/well 
overnight.  Phagocytosis of serum-opsonized (A) and non-serum-opsosonized (B) FITC-
P. aeruginosa was assessed as described in Materials and Methods (* p<0.05, ** p<0.01,  
*** p<0.001; Panel A n=10 per group, panel B n=5 per group). 
 
 
Myeloid-specific ablation of PTEN expression in BMT mice 
Myeloid-specific ablation of PTEN enhances lung phagocyte function and 
pulmonary host defense against Gram-negative bacterial infections (1, 2); however, it is 
not known whether similar mechanisms are relevant in the setting of BMT.   Since our 




phagocytosis in vitro (Fig. 5.2), we generated myeloid-specific PTEN KO mice to assess 
whether reconstituting PTEN deficient bone marrow into irradiated WT mice would 
restore host defense function in AMs.  To generate myeloid-specific PTEN KO mice, we 
obtained mice homozygous for a ―floxed‖ PTEN mutant allele containing loxP sites on 
either side of exon 5 encoding the phosphatase domain.  The PTEN floxed mice were 
bred to myeloid-specific Cre mice, which express the Cre recombinase gene under the 
control of the lysozyme M (LysM) promoter.  As previously described, mice bred to 
express two copies of the floxed PTEN allele and at least one copy of LysM-Cre 
recombinase are deficient in PTEN expression  in cells of the myeloid lineage (2, 9).  
Furthermore, these mice do not display an abnormal phenotype and are viable, fertile, and 
normal sized (2, 9).   
To verify PTEN ablation in our BMT model, AMs were harvested from non-
transplanted WT control mice and lethally TBI WT mice transplanted with either WT 
bone marrow (WT BMT) or myeloid-specific (conditional) PTEN KO bone marrow 
(PTEN CKO BMT).  PTEN protein expression was comparable in both control and WT 
BMT AMs (Fig. 5.3).  As expected, PTEN protein expression was ablated in AMs from 
PTEN CKO BMT mice (Fig. 5.3). Similar results were observed in recruited lung 





Figure 5.3: PTEN expression is ablated in AMs from PTEN CKO BMT mice. 
Whole-cell lysates were prepared from control, WT BMT, and PTEN CKO BMT AMs 
following 1h SFM adherence.  PTEN and β-actin protein expression were analyzed by 
Western blot.  Ablation of PTEN was verified in this manner for all experiments using 
PTEN CKO BMT mice. 
 
AMs from PTEN CKO BMT mice display enhanced opsonized phagocytosis and killing of 
P. aeruginosa, despite overproduction of PGE2 
We next performed experiments to determine whether myeloid-specific disruption 
of PTEN could improve opsonized phagocytosis and killing of P. aeruginosa in BMT 
AMs.  We found that AMs from PTEN CKO BMT mice displayed restored phagocytosis 
of serum-opsonized FITC-P. aeruginosa in vitro relative to WT BMT AMs (Fig. 5.4, 
panel A).  Furthermore, WT BMT AMs had increased survival of ingested P. aeruginosa 
relative to control AMs, indicating defective bacterial killing ability (Fig. 5.4, panel B).  
However, the amount of surviving bacteria was significantly lower in PTEN CKO BMT 
AMs compared to control AMs, suggesting bacterial killing is not only restored in AMs 
from PTEN CKO BMT mice but enhanced (Fig. 5.4, panel B).  Interestingly, AMs from 
PTEN CKO BMT mice produce significantly more PGE2 than both control and WT BMT 




suggest that PTEN ablation in AMs restores phagocytosis of serum opsonized bacteria 
post-BMT, despite AM overproduction of PGE2.   
 
 
Figure 5.4: Restored AM phagocytosis and killing of P. aeruginosa in PTEN CKO 
BMT mice, despite AM overproduction of PGE2 
Bone marrow from WT or myeloid-specific PTEN CKO mice was transplanted into 
lethally irradiated WT recipients.  WT control, WT BMT (WT>WT), and PTEN CKO 
BMT (PTEN CKO>WT) AMs were harvested and cultured at 2 x 10
5
 cells/well 
overnight.  Phagocytosis of serum-opsonized FITC-P. aeruginosa (A) and killing of 
serum opsonized P. aeruginosa (B) was assessed as described in Materials and Methods 
(** p<0.01, *** p<0.001; n=7-10 per group).  PGE2 levels were also measured in 
overnight culture supernatants by EIA as described in Materials and Methods (C) (* 






PTEN ablation improves but does not fully restore non-opsonized phagocytosis in AMs 
post-BMT 
 Our results with the PTEN inhibitor, bpV(pic), suggest that PTEN function may 
be less important for non-opsonized phagocytosis of bacteria.  To verify this with the 
genetic ablation, AMs were harvested from control, WT BMT and PTEN CKO BMT 
mice, and phagocytosis of non-opsonized bacteria was tested in vitro (Figure 5.5).  
Similar to our findings in Figure 5.2, PTEN CKO BMT AMs showed improved 
phagocytosis when compared to WT BMT AMs.  However, this improvement in 
phagocytic ability was not restored to control AM levels.  Thus, BMT-mediated increases 




Figure 5.5: Improved phagocytosis of non-opsonized P. aeruginosa in PTEN CKO 
BMT AMs 
AMs were harvested from control, WT BMT, and PTEN CKO BMT mice and cultured at 
2 x 10
5
 cells/well overnight.  Phagocytosis of non-serum-opsosonized FITC-P. 
aeruginosa was assessed as described in Materials and Methods (** p<0.01,  *** 






Restored AM and lung TNF-α levels in PTEN CKO BMT mice 
AMs from neutropenic myeloid-specific PTEN KO mice display enhanced 
proinflammatory cytokine profiles, including increased production of TNF-α, relative to 
neutropenic WT mice (155).  Because TNF-α is a key proinflammatory mediator in 
pulmonary host defense against P. aeruginosa and can activate bacterial killing 
mechanisms in macrophages (4, 11, 12), we measured TNF-α levels in AM overnight 
culture supernatants and lung homogenates from mice challenged with an acute P. 
aeruginosa lung infection.  As previously reported (106, 159), defective TNF-α 
production was observed in WT BMT AMs and lung homogenates relative to control 
samples (Figs. 5.6, panels A and B).  However, PTEN CKO BMT mice displayed 
improved  AM TNF-α production (Fig. 5.6, panel A), and lung homogenates from 
infected mice had fully restored TNF-α levels (Fig. 5.6, panel B).  
 
 
Figure 5.6: PTEN CKO BMT mice display improved TNF-α production. 
TNF-α production was measured by ELISA as described in Materials and Methods using 
AM overnight culture supernatants (A) and lung homogenates from mice 24h post-i.t. P. 






Improved bacterial clearance in PTEN CKO BMT mice following P. aeruginosa infection 
To determine whether PTEN CKO BMT mice display improved bacterial 
clearance post-BMT, we challenged control, WT BMT, and PTEN CKO BMT mice with 
a sublethal P. aeruginosa lung infection.  24 hours post-infection, bacterial burden was 
assessed in lung and blood samples.  In WT BMT mice, bacterial burden was 
significantly higher in lung and blood samples relative to control (Fig. 5.7, panels A and 
B).  In PTEN CKO BMT mice, bacterial burden was significantly reduced in both lung 
and blood samples relative to WT BMT mice, although not fully restored to control levels 
(Fig. 5.6, panels, A and B).  We speculate that the reason PTEN CKO BMT mice have an 
intermediate phenotype is that the acute in vivo infection model relies heavily on AM 





Figure 5.7: Improved bacterial clearance in PTEN CKO BMT mice following P. 
aeruginosa pneumonia 
Mice were i.t. injected with a 50 μL dose of 5 x 10
5
 CFU P. aeruginosa 5-6 weeks post-
BMT.  24h following infection, bacterial burden of whole lung (A) and blood (B) 
samples from each mouse was assessed by CFU assay (* p<0.05, ** p<0.01,  *** 
p<0.001; n=9-10 mice per group). 
 
 IRAK-M expression is elevated in both WT BMT and PTEN CKO BMT AMs 
 We previously demonstrated that in response to increased PGE2 signaling, BMT 
AMs display elevated expression of IRAK-M, a well described negative regulator of 
TLR/IL-1R signaling, (Fig. 4.1).  Furthermore, we found that despite overproduction of 
PGE2, ablation of IRAK-M in the hematopoietic compartment of BMT mice fully 
restores BMT AM phagocytosis of non-opsonized bacteria, killing, and production of 




partial restoration of non-opsonized phagocytosis in PTEN CKO BMT AMs was the 
result of elevated IRAK-M expression.  IRAK-M protein expression was assessed in 
AMs from control, WT BMT, and PTEN CKO BMT mice.  IRAK-M protein expression 
was significantly elevated in both WT BMT and PTEN CKO BMT AMs compared to 
control AMs (Fig. 5.8). These data highlight the idea that following BMT, IRAK-M may 
play a critical role in the negative regulation of non-opsonized phagocytosis, whereas 
PTEN primarily inhibits pathways of opsonized phagocytosis. 
 
Figure 5.8: Elevated IRAK-M expression in both WT BMT and PTEN CKO BMT 
AMs 
Whole-cell lysates were prepared from control, WT BMT, and PTEN CKO BMT AMs 
following 1h SFM adherence.  IRAK-M and β-actin protein expression were analyzed by 




Lung leukocyte composition in PTEN CKO BMT mice 
We next wanted to assess the total number of leukocytes and the frequency of 
leukocyte populations in the lungs of control, WT BMT, and PTEN CKO BMT mice at 
baseline and 24 hours following P. aeruginosa pneumonia.  Total lung leukocyte 
numbers were increased in uninfected PTEN CKO BMT mice relative to uninfected WT 




numbers were comparable between groups (Fig. 5.9, panel B).  Interestingly, a shift was 
observed in whole lung macrophage and neutrophil counts in uninfected PTEN CKO 
BMT mice (Fig. 5.9, panel C).  We found that the percentage of macrophages was 
significantly reduced and neutrophils increased relative to both control and WT BMT 
lungs (Fig 5.9, panel C).  Following infection, however, the percentages of neutrophils, 
macrophages, and lymphocytes were comparable between groups (Fig. 5.9, panel D).   
 
 
Figure 5.9: Lung leukocyte composition pre- and post-P. aeruginosa infection 
Control, WT BMT, and PTEN CKO BMT mice were i.t. injected with a 50 μL dose of 5 
x 10
5
 CFU P. aeruginosa.  Lung samples were harvested from both uninfected and 
infected mice 24h later, and lung leukocytes were isolated, counted and stained for 
differential cell analysis as described in Materials and Methods.  Total lung leukocyte 
count in naïve (A) and infected (B) mice.  Percentage of macrophages/monocytes, 
neutrophils, lymphocytes, and eosinophils in the lungs of naïve (C) and infected (D) mice 
(* p<0.05, *** p<0.001; n=4 per group). 
 
Neutrophil function is improved in PTEN CKO BMT mice 
 
Previous studies have suggested that PTEN-deficient neutrophils have improved 




neutrophil numbers in the lung at baseline, we wanted to assess the functional status of 
these phagocytes with regard to bacterial killing.    Relative to control neutrophils, WT 
BMT neutrophils displayed impaired bacterial killing of serum opsonized P. aeruginosa, 
and this defect was restored in the absence of PTEN post-BMT (Fig. 5.10).  Thus, despite 
the fact that PTEN CKO BMT mice have increased neutrophils in the lung at baseline 
and display normal killing of serum-opsonized P. aeruginosa, the in vivo clearance of 
bacteria in these mice is still not completely restored.  In total, these data highlight the 
idea that impaired mechanisms of non-opsonized phagocytosis are likely contributing to 
the partial restoration of host defense against acute of P. aeruginosa lung infection in 
PTEN CKO BMT mice. 
 
Figure 5.10: Restored neutrophil killing of P. aeruginosa in PTEN CKO BMT mice 
Neutrophils were elicited to the lung and harvested by BAL from control, WT BMT, and 
PTEN CKO BMT mice as described in Materials and Methods.  Killing of serum 
opsonized P. aeruginosa was assessed in neutrophils as described in Materials and 





AMs are the primary immune cell type in the alveolar space and serve as the first 
line of cellular defense against inhaled pathogens (3-5).  Therefore, any defects in AM 
phagocytosis/killing and production of inflammatory signals hinder the ability of the host 
to clear pathogens entering the lung and inhibit effector immune responses.  In the case of 
HSCT, donor-derived AMs reconstituting the lung airspaces have a significantly 
impaired ability to ingest and kill bacterial pathogens (104, 106).  Thus, this deficiency in 
immune function creates a lung environment that is highly susceptible to pathogenic 
organisms, such as P. aeruginosa.   
Our previous work has shown that overproduction of PGE2 in lung and AMs post-
BMT directly impairs AM host defense (68).  One particular effector in the PGE2 
signaling cascade, PTEN, has recently been shown to inhibit AM phagocytosis and 
killing of IgG-opsonized particles by negatively regulating the FcγR signaling pathway in 
control mice (120).  In this paper, we show a similar mechanism may be involved post-
BMT, where PGE2 is overproduced by AMs and signals an increase in the lipid 
phosphatase activity of PTEN.  Furthermore, we show that PTEN activity inhibits BMT 
AM phagocytosis of both serum and non-serum opsonized P. aeruginosa, although it 
appears that PTEN may play a more critical role in the negative regulation of opsonized 
phagocytosis.  In addition, we show that myeloid-specific ablation of PTEN restores 
bacterial killing functions in both AMs and neutrophils post-BMT. 
Our data demonstrate that BMT AMs have increased PTEN activity relative to 
non-transplant control AMs (Fig 5.1, panel A).  As PGE2 has been shown to increase 




AM overproduction of PGE2 was mediating this increase in PTEN activity.  
Indomethacin treatment, which inhibits COX-2 synthesis of prostaglandins, effectively 
abrogated the increase we observed in PTEN activity (Fig. 5.1, panel A).  Enhanced 
PTEN activity translated into the functional consequence of suppressed AKT activity 
following FcγR stimulation in BMT AMs, but we observed that AKT function could be 
restored with indomethacin pretreatment (Fig 5.1, panel B).  Thus, these data suggest that 
PGE2 may be increasing BMT AM PTEN activity and diminishing AKT activation 
following FcγR activation.   
During acute bacterial lung infections, AM phagocytosis likely involves uptake of 
bacteria that is either non-opsonized or opsonized by serum-derived complement (5, 
106).  Interestingly, it has previously been shown that PI3K activity, which is tightly 
regulated by PTEN, is involved in both complement-mediated and non-opsonized 
phagocytosis (98, 99, 211) in non-transplant settings.   Therefore, we examined whether 
inhibiting PTEN activity could restore BMT AM phagocytosis of both serum and non-
serum opsonized FITC-P. aeruginosa.  Pharmacologic PTEN inhibition significantly 
increased phagocytosis of non-opsonized P. aeruginosa, but did not restore levels to 
those seen in control AMs.   In contrast, pharmacologic inhibition of PTEN  fully 
restored serum-opsonized phagocytosis to control levels (Fig. 5.2).  It is likely that the 
presence of IgG (in addition to complement) in our immune serum contributed to the 
greater magnitude of improvement we observed in phagocytosis of serum-opsonized 
bacteria in bpV(pic)-treated BMT AMs compared to non-opsonized bacteria.  As 
discussed below, these pharmacologic results were also corroborated by studies using 




Previous studies have shown that in murine models of neutropenia, myeloid-
specific ablation of PTEN can enhance opsonized bacterial clearance as well as 
proinflammatory cytokine production in AMs (155).   Our data demonstrate a similar 
enhancement of host defense following transplantation of myeloid-specific PTEN KO 
bone marrow into lethally irradiated WT recipients.  Despite overproduction of PGE2 
(Fig. 5.4, panel C), we found that AM phagocytosis and killing of serum opsonized P. 
aeruginosa is restored (Fig. 5.4), and that AM TNF-α production is improved in the 
absence of PTEN expression post-BMT (Fig. 5.6, panel A).  Interestingly however, 
phagocytosis of non-opsonized bacteria is not fully restored in the PTEN CKO BMT 
AMs (Fig. 5.5).  Furthermore, bacterial clearance in mice challenged with P. aeruginosa 
lung infection is only partially recovered in PTEN CKO BMT mice (Fig. 5.7), despite the 
fact that lung TNF-α levels are restored (Fig. 5.6, panel B).  Taken together, these data 
suggest that PTEN may be necessary for PGE2 to mediate its suppressive effects on BMT 
AM function against opsonized targets; however, BMT AMs retain defects in non-
opsonized phagocytosis that are likely PTEN-independent.  
Following infection, total lung leukocyte numbers and neutrophil recruitment are 
similar in both WT BMT and PTEN CKO BMT mice (Fig. 5.9, panels B and D).  
However, uninfected PTEN CKO BMT mice display an increase in total leukocyte 
number relative to WT BMT mice (Fig. 5.9, panel A).  We also found that significantly 
more neutrophils and fewer macrophages are present in the lungs of uninfected PTEN 
CKO BMT mice compared to both uninfected control and WT BMT mice (Fig. 5.9, panel 
C).  In figure 5.10, we demonstrate that neutrophil killing of serum opsonized P. 




results indicate that PTEN CKO BMT mice have fully restored AM phagocytosis of 
serum opsonized bacteria, more neutrophils at baseline, and normal neutrophil killing 
ability.   
Despite these improvements in host defense, in vivo clearance of P. aeruginosa in 
PTEN CKO BMT mice is not fully restored to control levels.  We believe the reason for 
this is best explained by the observation that non-opsonized bacterial phagocytosis is still 
impaired in PTEN CKO BMT AMs relative to control AMs (Figure 5.5) .  This is likely 
due to the fact that IRAK-M is elevated in the AMs from PTEN CKO BMT mice (Fig. 
5.8).  We have previously shown that increased PGE2 production post-BMT elevates 
IRAK-M expression in AMs (Fig. 4.3).  Transplantation of IRAK-M-/- bone marrow into 
WT mice fully restored in vivo clearance of P. aeruginosa to control levels following an 
acute (24 hour) infection.  Putting our two studies together, we conclude that non-
opsonized phagocytosis of P. aeruginosa plays a critical role in clearance of acute 
infection and is negatively regulated by PGE2-induced IRAK-M.  While we believe the 
partial restoration of bacterial clearance in our PTEN CKO BMT mice is best explained 
by our observation that non-opsonized phagocytosis by AMs is not fully recovered, 
another possibility is that neutrophils in the PTEN CKO BMT may be displaying 
prolonged survival (2, 158)  resulting in increased neutrophil damage to the lung, delayed 
immune resolution, and diminished tissue repair.  Indeed, since PTEN is a critical 
regulator of cellular apoptosis, this may well be occurring.  
As mentioned, IRAK-M protein expression is elevated in both WT BMT and 
PTEN CKO BMT AMs relative to control AMs (Fig. 5.8). These data suggest PGE2-




host defense functions.  An alternative hypothesis could be that IRAK-M is an upstream 
regulator of PTEN function.  Overall, our data support a model where PGE2 signaling 
induces two unique pathways which regulate host defense.  The upregulation of PTEN by 
PGE2 primarily causes inhibition of opsonized AM phagocytosis and PMN killing post-
BMT.  Simultaneously, PGE2-mediated upregulation of IRAK-M inhibits non-opsonized 
phagocytosis in AMs post-BMT. 
Our data have several important implications.  First, susceptibility to P. 
aeruginosa infection is widely considered to be a consequence of neutropenia (207).  
While it is clear that neutropenia can increase host susceptibility to infection, our data 
clearly demonstrate that isolated defects in AM phagocytosis of non-opsonized bacteria 
can also render the host susceptible to this infection.  Our findings are supported by 
previous observations demonstrating that clodronate liposome depletion of AMs  
negatively impacted lung host defense against P. aeruginosa in vivo (207).  Our results 
also highlight the fact that PGE2 signaling initiates unique pathways for the inhibition of 
opsonized versus non-opsonized bacteria.  While PTEN activation negatively regulates 
phagocytosis of serum opsonized bacteria and has modest effects on non-opsonized 
phagocytosis in our model, it appears that IRAK-M elevation mediates more pronounced 
inhibition of phagocytosis of non-opsonized particles.  Thus, these data are the first to 
highlight divergent pathways by which PGE2 can inhibit opsonized and non-opsonized 
phagocytosis.  
Overall, our data suggest that PGE2 may inhibit multiple mechanisms of 
phagocytosis in BMT AMs via the upregulation of PTEN activity and the induction of 




opsonized bacterial phagocytosis in AMs and also restores neutrophil killing post-BMT.  
However, ablation of PTEN may not be sufficient to fully restore host defense against 
acute P. aeruginosa infection, given that non-opsonized phagocytosis by PTEN CKO 
BMT AMs appears to be inhibited by elevated IRAK-M expression.  As such, our results 
suggest that a better strategy to restore host defense post-BMT may be to target the 
production of PGE2 or EP2 receptor signaling.  In fact, we have already demonstrated 
that pharmacologic blockade of PGE2 production by indomethacin post-BMT can fully 
restore host defense (68).  An important future goal will be to determine whether these 
same PGE2-induced alterations are present in human AMs post-HSCT and if therapeutic 
approaches to block PGE2 production or signaling can improve host defense by reversing 









CHAPTER 6: Conclusion 
 
Summary of Results 
Conditioning Regimen Studies 
Our previous work demonstrated that pulmonary host defense against acute P. 
aeruginosa infection is impaired post-BMT (68).  However, our TBI + T conditioning 
regimen used to ablate host bone marrow in our studies did not mimic clinical practice (8, 
174-176).  Our current work demonstrates that following 13 Gy TBI conditioning and 
infusion of whole bone marrow alone (no addition of splenic T cells), mice are fully 
donor cell reconstituted at 5 weeks post-BMT (Table 3.1).  Furthermore, use of 
busulfan/cyclophosphamide dual chemotherapy regimens, as opposed to individual 
chemotherapy regimens, was the only chemotherapy regimen that provides significant 
reconstitution of donor-type AM and peripheral cells (Table 3.2).   Similarly, use of dual 
chemotherapy was the only chemotherapy-based protocol that induces overproduction of 
PGE2 and PGI2 in AMs post-BMT (Fig. 3.3).  
AMs from BMT mice conditioned with either TBI or dual chemotherapy were 
similarly defective in phagocytosis relative to control AMs, and this inhibition was 
directly related to overproduction of PGE2 (Fig. 3.4, panel B).  Reduced clearance of P. 
aeruginosa following acute lung infection was also observed in both TBI and dual 
chemotherapy conditioned mice (Fig. 3.4, panel B).  Taken together, these data 




impaired pulmonary host defense mediated by overproduction of PGE2. Ultimately, these 
results offer further clinical relevance to our murine model of BMT and suggest that our 
findings are applicable to multiple conditioning protocols and result in significant donor-
cell reconstitution.   
 
IRAK-M Studies 
Our work suggests a role for IRAK-M in PGE2-induced immunosuppression post-
BMT.  We are the first to show that IRAK-M expression is upregulated in BMT AMs, 
and this phenotype is related to increased PGE2 signaling (Fig. 4.1 and 4.3).  
Furthermore, we demonstrate an inhibitory role for IRAK-M in pulmonary host defense 
post-BMT, given that genetic ablation of IRAK-M in the bone marrow restores AM 
function and pulmonary host defense against acute P. aeruginosa infection.   
Restored bacterial clearance and improved survival rate following P. aeruginosa 
lung infection in IRAK-M -/- BMT mice was not explained by enhanced neutrophil 
recruitment to the lung during early infection (Fig. 4.6) or alterations in the frequency of 
lymphocyte populations in the lungs before infection (Fig. 4.7).  Additionally, although 
neutrophils expressed IRAK-M, there was no clear evidence that recruited lung 
neutrophils upregulated IRAK-M in response to BMT (Fig. 4.1).    Moreover, our data do 
not suggest a role for altered AM expression of TLRs or scavenger receptors in enhanced 
host defense displayed by IRAK-M -/- BMT mice (Fig. 4.10).  Our data do indicate, 
however, that IRAK-M -/- BMT AMs displayed restored non-opsonized phagocytosis, 




defense in IRAK-M -/- BMT AMs was observed despite elevated EP2 receptor 
expression and overproduction of PGE2 in AMs (Fig. 4.11).  Overall, these data suggest 
that PGE2 may require IRAK-M to inhibit AM function against non-opsonized 
pathogens, and therefore, IRAK-M -/- BMT AMs may not be responsive to PGE2-
induced immunosuppression despite AM upregulation of the inhibitory EP2 receptor.  
Our work in the PTEN studies, described below, suggests that IRAK-M may be a unique 
inhibitor of non-opsonized phagocytosis pathways.   
 
PTEN Studies 
Similar to our IRAK-M studies, our data demonstrate that PTEN also plays a role 
in PGE2-mediated suppression of AM host defense post-BMT.  Relative to control AMs, 
BMT AMs had increased PTEN activity in response to increased PGE2 signaling (5.1).  
Furthermore, pharmacologic inhibition of PTEN activity using bpV(pic) fully restored 
phagocytosis of serum-opsonized P. aeruginosa but only moderately improved non-
opsonized phagocytosis (Fig. 5.2).  In the absence of PTEN expression post-BMT, AM 
phagocytosis and killing of serum opsonized P. aeruginosa was restored (Fig. 5.4), and 
AM TNF-α production was improved (Fig. 5.6), despite overproduction of PGE2.  
Similar to our bpV(pic)-treated WT BMT AMs, non-opsonized phagocytosis of P. 
aeruginosa was only partially restored in PTEN CKO BMT AMs (Fig. 5.5).  
Additionally, we found that bacterial clearance was partially restored (Fig. 5.7) and lung 
TNF-α levels were improved in PTEN CKO BMT mice following P. aeruginosa lung 




Enhanced neutrophil recruitment following P. aeruginosa pneumonia was not 
observed in PTEN CKO BMT mice; however, increased numbers of neutrophils were 
found in the lungs of PTEN CKO BMT mice prior to infection (Fig. 5.9), and bacterial 
killing of serum-opsonized P. aeruginosa was fully restored in these cells (Fig. 5.10). 
The increased percentage of neutrophils is likely due to the increased production of MIP-
2 secreted by AMs in PTEN CKO BMT mice relative to both control and WT BMT mice 
(data not shown).    
Finally, a role for PTEN in PGE2-mediated elevation of IRAK-M was also 
assessed, and we found that IRAK-M was elevated in both WT BMT and PTEN CKO 
BMT AMs relative to control AMs (Fig. 5.8).  It is possible that IRAK-M may 
specifically inhibit non-opsonized phagocytosis pathways, and thus, non-opsonized 
phagocytosis in PTEN CKO BMT AMs remains impaired while serum-opsonized 
phagocytosis is restored.  It is also interesting to speculate that this defect in non-
opsonized phagocytosis likely accounts for the intermediate improvement in host defense 
noted in the PTEN CKO BMT mice post-acute P. aeruginosa lung infection.  Overall our 
data suggest that upregulation of PTEN activity may be necessary for PGE2 to mediate 
much of its suppressive effects on BMT AM function towards opsonized pathogens and 
overall pulmonary host defense.  Furthermore, IRAK-M expression may be upregulated 
independently of PTEN in response to PGE2 signaling, given that ablation of either PTEN 
or IRAK-M has differential effects on BMT AM phagocytosis and clearance of P. 






Critical Review and Future Directions 
Conditioning Regimen Studies 
 Conditioning regimens used for HSCT in the United States normally employ 
either high dose chemotherapy or a combination of TBI and chemotherapy (7).  Thus, our 
model of TBI BMT does not accurately reflect how patients are conditioned prior to HSC 
infusion.  Therefore, comparing the effect of TBI and chemotherapy conditioning on 
immune reconstitution and host defense function was critical in determining the clinical 
relevance of our TBI conditioning regimen.   
Our results indicate that compared to TBI, dual chemotherapy conditioning yields 
a significantly lower frequency of donor-derived cells 5 weeks post-BMT.  Despite this 
altered level of chimerism in our chemotherapy conditioned mice, the effect of TBI and 
chemotherapy on immune function is similar in that PGE2-mediated impairment of AM 
host defense was observed in both TBI and chemotherapy conditioned mice.  
Interestingly, preliminary data suggest that following BMT, host-derived AMs display 
increased PGE2 production (Fig. 6.1A) and impaired phagocytosis of non-opsonized 
bacteria (Fig. 6.1B).   These results suggest that even if the conditioning regimen does not 
result in maximal donor cell reconstitution, the process of BMT still induces significant 
impairment of both donor and host cell function.  Therefore, our decision to use TBI as 
the main conditioning protocol for our studies was based primarily on our ability to 
examine the effect of transplant largely on donor-derived cells as opposed to an evenly 







Figure 6.1: Elevated PGE2 production and impaired phagocytosis in host-derived 
and donor-derived AMs post-BMT 
5 weeks post-BMT, AMs from B6 (CD45.1) > B6 (CD45.2) BMT mice conditioned with 
only 8 Gy of TBI and non-transplant B6 (CD45.2) control mice were harvested.  Donor 
CD45.1 AMs were positively selected by MACS.  Control, donor, and host AMs were 
plated 2 x 10
5
 cells/well.  Overnight supernatants were collected and analyzed for PGE2 
levels by EIA (A).  Phagocytosis of AMs was then assessed following incubation with 
FITC-E. coli as described in Materials and Methods (B) (*** p<0.001; n=2-3 per group). 
 
Our conditioning regimen studies provide much needed insight into the effect of 
chemotherapy conditioning on pulmonary host defense in BMT mice.  However, multiple 
aspects of PGE2-mediated impairment of pulmonary host defense must still be addressed.  
In our previous studies, indomethacin treatment restored bacterial clearance in TBI BMT 
mice challenged with P. aeruginosa lung infection (68).  The effect of indomethacin 
treatment on dual chemo BMT mice, however, was not determined in our present studies.  
Future work will need to address this point in order to fully assess the effect of 
overproduction of PGE2 on pulmonary host defense in both TBI and chemotherapy 
conditioned mice.  Furthermore, our current studies do not determine the effect of both 




phagocytosis of non-opsonized bacteria.  These experiments will be required to fully 
support our claim that PGE2 mediates similar impairment of pulmonary host defense in 
both TBI and chemotherapy conditioned BMT mice.   
Additionally, mechanisms of PGE2-mediated suppression of pulmonary host 
defense need to be determined in both conditioning groups.  Future studies should 
address roles for known effectors in the PGE2 signaling pathway, such as cAMP, EPAC-
1, and PKA.  Also roles for IRAK-M and PTEN in AM and neutrophil host defense 
should be considered in both models.  Ultimately, these results would give us a more 
accurate picture of the similarities and differences in pulmonary host defense following 
TBI and dual chemotherapy conditioning. 
Some limitations to our conditioning regimen studies remain.  Primarily, we have 
not identified why PGE2 is overproduced following BMT and whether this induction is 
lung specific.  The literature indicates that PGE2 production is induced following TBI or 
chemotherapy/TBI combination treatment in HSCT patients (110) and following 
radiation treatment in cancer patients (212).  It is speculated that this induction is related 
to epithelial cell damage which occurs during TBI and myeloablative therapy.  Currently, 
we have only demonstrated that PGE2 synthetic enzymes are elevated in AMs from mice 
conditioned with TBI (Fig. 4.2).  Future studies will need to explore whether irradiation 
can induce production of PGE2 in cultured AECs.  Furthermore, we will need to examine 
whether irradiated AECs or AECs from TBI or dual chemotherapy conditioned BMT 
mice are capable of inducing PGE2 production in co-cultured phagocytes.  If positive 
results are produced from these experiments, we would then compare host defense 




induction is lung-specific, serum PGE2 levels would be measured in control and BMT 
mice, and EP receptor expression profiles would be assessed among various tissue 
specific macrophages to ascertain whether phagocytes outside of the lung are also be 
responsive to increased PGE2 production.   
In addition, it remains unknown whether increased PGE2 production is induced in 
the lungs of HSCT patients and whether this may mediate impaired pulmonary innate 
immunity.  Thus, future work will specifically examine AM and BAL PGE2 levels in 
normal subjects and patients given either an allogeneic or autologous HSCT.  If PGE2 
levels are elevated in the lungs of HSCT patients, we would then assess AM host defense 
function in the presence or absence of indomethacin. 
 
IRAK-M Studies 
 Our current work describes a critical role for IRAK-M in AM host defense 
following BMT.  However, multiple areas of this work require further study.  Primarily, 
our future work must incorporate experiments that would: 1) provide insight into the 
mechanism of PGE2-mediated upregulation of IRAK-M expression and 2) identify 
additional factors induced during BMT that may also play a role in the upregulation of 
IRAK-M. 
 PGE2 signaling through the inhibitory EP2 and EP4 receptors activates the cAMP 
signaling cascade.  Effectors of this signaling pathway mainly include EPAC-1 and PKA.  
However, we have not established roles for any of these molecules in the upregulation of 
IRAK-M.  Preliminary data suggest that cAMP increases IRAK-M expression in non-




AC activator forskolin.  Interestingly, we have found in other preliminary experiments 
that following PGE2 treatment, BMTs AMs display diminished cAMP production in the 
absence of IRAK-M (Fig. 6.3).  These data suggest to us that IRAK-M may be 
upregulated via the cAMP signaling cascade to negatively regulate factors that inhibit 
cAMP.  Future studies will verify whether cAMP can elevate IRAK-M expression and if 
so, determine whether this cAMP-mediated upregulation involves PKA or EPAC-1.  
Additionally, we would like to assess whether cAMP degradative phosphodiesterases are 
upregulated in IRAK-M -/- deficient AMs as a possible explanation for diminished 
cAMP production in IRAK-M -/- BMT AMs.   
 
 
Figure 6.2: AC-mediated increases in cAMP elevate IRAK-M expression in non-
transplant AMs.   
AMs from non-transplant mice were plated 5 x 10
5
 cells/well overnight in the presence or 
absence of 10 nM forskolin in SFM.  Protein lysates of AMs were prepared for Western 





Figure 6.3: Diminished cAMP production in IRAK-M -/- BMT AMs following 
stimulation with PGE2 
AMs from control, WT BMT, and IRAK-M -/- BMT mice were plated 5 x 10
5
 cells/well 
in CM overnight, and the following, day AMs were treated with 1 μM PGE2 for 15 mins.  
AMs lysates were then prepared for cAMP EIA as described in Materials and Methods 
(** p< 0.01; *** p<0.001; n= 7-8 per group). 
 
 Our data also indicate that WT BMT AMs display defective phagocytosis of non-
opsonized P. aeruginosa and that this impairment is restored in the absence of IRAK-M 
(Fig. 4.8).  We did not identify, however, what phagocytic receptors may be differentially 
expressed among WT BMT and IRAK-M -/- BMT AMs.  Future experiments will need 
to identify the receptors involved in AM phagocytosis of non-opsonized P. aeruginosa 
and whether they are altered in the setting of BMT.  Moreover, pulmonary host defense 
against acute P. aeruginosa lung infection involves multiple humoral opsonins that were 
not addressed in any of our studies.  Therefore, it will be important to consider roles for 
complement and collectins in phagocytosis of P. aeruginosa in vitro, since these humoral 
opsonins may play an important role in clearance of P. aeruginosa from the lung during 




that are restored in IRAK-M -/- BMT AMs must be examined.  Future experiments can 
employ measurement of ROS, tracking of phagosome maturation and lysosomal fusion, 
and quantification of antimicrobial factors produced in the lung during infection (such as 
lactoferrin, defensins, and lysozyme).   
 Finally, some experimental limitations to our studies impeded our ability to fully 
assess the role of IRAK-M in lung phagocyte host defense post-BMT.  Neutrophil 
function is severely impaired in BMT mice (68); however, due to our neutrophil 
recruitment protocol, we were unable to meaningfully assess whether this defect was 
related to PGE2-mediated elevation of IRAK-M.  In our studies, neutrophil recruitment 
involves i.t. injection of LPS, and it appeared that the LPS recruitment signal maximally 
upregulated IRAK-M in both control and WT BMT neutrophils (Fig. 4.1).  Other 
neutrophil recruiting agents, such as chemokines or thioglycollate, may be tested in the 
future to overcome this problem.  Additionally, ablation of IRAK-M in our model was 
not myeloid-specific and ignores the effect of IRAK-M deficiency on lymphoid-derived 
cells and the interaction of these cell types with lung phagocytes during infection.  In 
order to address this concern, future studies would require the use of conditional IRAK-
M knockout systems that have not yet been developed. 
  
PTEN Studies 
 Previous work demonstrates that PGE2 signaling through the EP2 receptor 
elevates PTEN activity and inhibits FcγR-mediated phagocytosis and bacterial killing 
(120).  Our work suggests a similar mechanism of inhibition of AM host defense post-




lipid phosphatase activity is elevated in BMT AMs as a result of increased PGE2 
production (Fig. 5.1, panel A).  Previous work identifies a role for EPAC-1 and SHIP-1 
in PGE2-mediated increases in PTEN activity (120).  It remains unknown whether these 
molecules are also upregulating PTEN activity in BMT AMs or if alternative effectors 
are involved, such as PKA or even IRAK-M (120).    Therefore, future experiments will 
need to examine the effect of PKA and EPAC-1antagonists on PTEN activity in BMT 
AMs.  Furthermore, future experiments must assess whether IRAK-M is acting upstream 
in the PGE2 signaling pathway to regulate PTEN activity or if IRAK-M is regulated 
independently of PTEN to inhibit AM host defense.  To verify this, we would need to 
confirm that PTEN activity is not elevated in IRAK-M -/- BMT AMs as well as IRAK-M 
-/- non-transplant AMs treated with PGE2.   
SHIP-1 phophosphatase activity has also been shown to contribute to PTEN 
activation by dephosphorylating PTEN on tyrosine residues.  It remains to be explored 
what other post-translational modifications of PTEN are regulated by PGE2 signaling and 
if these modifications are applicable to the setting of transplant.  Future experiments will 
confirm whether alterations in the phosphorylation state of PTEN are also present in 
BMT AMs. 
 Previous work has demonstrated that diminished activation of downstream 
effectors in the PI3K signaling pathway, such as AKT and ERK-1/2, is observed in AMs 
following treatment with PGE2 (120).  Our studies demonstrate that AKT activation is 
also diminished in BMT AMs due to increased PGE2 production (Fig. 5.1, panel B).  It is 
currently assumed that diminished AKT activation is due to elevated PTEN activity in 




not identified whether overproduction of PGE2 in BMT AMs reduces activation of other 
downstream effectors in the PI3K signaling pathway, such as Vav, Rac, Cdc, and ERK-
1/2.  Therefore, we plan to perform experiments where BMT AMs are treated with the 
PTEN inhibitor, bpV(pic), and phosphorylation of AKT is assessed.  Finally, we will 
assess whether activation of other effectors in the PI3K signaling pathway is reduced in 
BMT AMs and if treatment with indomethacin can restore activation of these molecules. 
 Aside from identifying signaling molecules associated with PGE2-mediated 
increases in PTEN activity, our future studies must also focus on whether PTEN can 
regulate pathways associated with non-opsonized or complement-mediated phagocytosis.  
Our data show that myeloid-specific ablation of PTEN enhances BMT AM phagocytosis 
of serum-opsonized P. aeruginosa (Fig. 5.4, panel A).  Furthermore, our data also 
demonstrate that non-opsonized phagocytosis is improved but not fully restored in PTEN 
CKO BMT AMs (Fig. 5.5).  This finding is important given that PTEN has not 
previously been shown to regulate non-opsonized phagocytosis.  Future experiments will 
confirm this finding and also determine whether PTEN can specifically regulate 
complement-mediated phagocytosis.  The latter experiments will involve use of 
complement opsonized bacteria in in vitro phagocytosis assays for control, WT BMT, 
and PTEN CKO BMT AMs.   
 Although PTEN appears to have some contribution to impaired non-opsonized 
phagocytosis in AMs post-BMT, we believe that IRAK-M may play a more critical role 
in the inhibition of this phagocytic pathway.  To verify this hypothesis, we plan to assess 
PTEN activity and serum opsonized phagocytosis in IRAK-M -/- BMT AMs.  




with IRAK-M-specific siRNAs may also provide further insight into the role of IRAK-M 
in the regulation of non-opsonized phagocytosis post-BMT.  
 Lastly, the role of neutrophils needs to be further clarified in improved pulmonary 
host defense in PTEN CKO BMT mice.  Our data demonstrate that PTEN CKO BMT 
mice have improved bacterial clearance and reduced bacteremia following P. aeruginosa 
lung infection (Fig. 5.7).  Although this improvement in host defense is quite significant, 
bacterial load in the lung and blood of PTEN CKO BMT mice is not restored to control 
levels.  This difference could be due to impaired non-opsonized phagocytosis in AMs.  
Alternatively, this difference may be related to increased neutrophil survival and damage 
in the lungs of PTEN CKO BMT mice.  PTEN is a critical negative regulator of cell 
survival and migration signals mediated by PI3K/AKT signaling (146, 153).  Therefore, 
future experiments will need to assess the level of neutrophil apoptosis in control, WT 
BMT, and PTEN CKO BMT mice following infection.   Furthermore, lung histology will 
also be performed to identify signs of neutrophil damage to lung tissue.  These 
experiments should help determine whether neutrophil damage is contributing to reduced 
bacterial clearance in the lung.   
 A few limitations were encountered in our PTEN studies.  Of major concern was 
the effect of lysozyme M disruption in the myeloid compartment of our WT BMT and 
PTEN CKO BMT mice.  Although the effect of lysozyme M disruption was minimized 
by using Cre heterozygous mice, it is not clear whether defects in pulmonary host defense 
in these mice were further exacerbated by reduced expression of this important 
antimicrobial factor.  Furthermore, residual expression of functional PTEN protein in our 




defense in these mice.  Lastly, it would also be interesting to measure IRAK-M 
expression in PTEN CKO BMT lung neutrophils to confirm the results we found in 
PTEN CKO BMT AMs.  However, we were again limited by the LPS recruitment 
signaling in the proper assessment of whether IRAK-M is elevated in neutrophils in 
response to BMT.   
 
Final Thoughts 
 Our model of syngeneic BMT has provided extensive insight into the various 
factors involved in impaired pulmonary innate immunity following transplant (Fig. 6.4).  
Moreover, we have been able to identify defects in host defense that are related 
specifically to the procedure of transplant as opposed to exogenous immunosuppressive 
factors or GVHD.   Future work will help to identify additional signaling molecules in the 
PGE2 signaling pathway that mediate the upregulation of IRAK-M and PTEN in BMT 
AMs.  Additionally, identifying a role for PGE2 in impaired pulmonary host defense in 






Figure 6.4: Roles for PTEN and IRAK-M in PGE2-mediated suppression of AM 
host defense  
Following BMT, AMs display increased PGE2 production and signaling via the EP2 
receptor.  This increase in PGE2 signaling results in upregulation of PTEN activity and 
IRAK-M expression in BMT AMs.  Ultimately, upregulation of these two effectors in the 
PGE2 signaling pathway inhibits host defense against P. aeruginosa via the suppression 
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